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Abstract
Standard approaches to analysing data in genome-wide association studies (GWAS)
ignore any potential functional relationships between genetic markers. In contrast gene
pathways analysis uses prior information on functional structure within the genome to
identify pathways associated with a trait of interest. In a second step, important single
nucleotide polymorphisms (SNPs) or genes may be identified within associated pathways.
The pathways approach is motivated by the fact that many genes do not act alone, but in-
stead have effects that are likely to be mediated through their interaction in gene pathways.
Where this is the case, pathways approaches may reveal aspects of a trait’s genetic archi-
tecture that would otherwise be missed when considering SNPs in isolation. Most path-
ways methods begin by testing SNPs one at a time, and so fail to capitalise on the potential
advantages inherent in a multi-SNP, joint modelling approach. Here we describe a dual-
level, sparse regression model for the simultaneous identification of pathways, genes and
SNPs associated with a quantitative trait. Our method takes account of various factors
specific to the joint modelling of pathways with genome-wide data, including widespread
correlation between genetic predictors, and the fact that variants may overlap multiple
pathways. We use a resampling strategy that exploits finite sample variability to provide
robust rankings for pathways, SNPs and genes. We test our method through simulation,
and use it to perform pathways-driven SNP selection in a search for pathways, genes and
SNPs associated with variation in serum high-density lipoprotein cholesterol (HDLC) lev-
els in two separate GWAS cohorts of Asian adults. By comparing results from both cohorts
we identify a number of candidate pathways including those associated with cardiomyopa-
thy, and T cell receptor and PPAR signalling. Highlighted genes include those associated
with the L-type calcium channel, adenylate cyclase, integrin, laminin, MAPK signalling
and immune function. Software implementing the methods described here, together with
sample data is available at http:// www2.imperial.ac.uk/∼gmontana/ psrrr.htm.
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Introduction
Much attention continues to be focused on the problem of identifying SNPs and genes influ-
encing a quantitative or dichotomous trait in genome wide scans [53]. Despite this, in many
instances gene variants identified in GWAS have so far uncovered only a relatively small part
of the known heritability of most common diseases [84]. Possible explanations include the
presence of multiple SNPs with small effects, or of rare variants, which may be hard to detect
using conventional approaches [84, 52, 28].
One potentially powerful approach to uncovering the genetic etiology of disease is moti-
vated by the observation that in many cases disease states are likely to be driven by multiple
genetic variants of small to moderate effect, mediated through their interaction in molecular
networks or pathways, rather than by the effects of a few, highly penetrant mutations [63].
Where this assumption holds, the hope is that by considering the joint effects of variants
acting in concert, pathways GWAS methods will reveal aspects of a disease’s genetic architec-
ture that would otherwise be missed when considering variants individually [86, 25]. In this
section we describe a sparse regression method utilising prior information on gene pathways
to identify putative causal pathways, along with the constituent SNPs and genes that may
be driving pathways association.
Sparse modelling approaches are becoming increasingly popular for the analysis of genome
wide datasets [65, 17, 3, 88]. Sparse regression models enable the joint modelling of large
numbers of SNP predictors, and perform ‘model selection’ by highlighting small numbers of
variants influencing the trait of interest. These models work by penalising or constraining the
size of estimated regression coefficients. An interesting feature of these methods is that dif-
ferent sparsity patterns, that is different sets of genetic predictors having specified properties,
can be obtained by varying the nature of this constraint. For example, the lasso [78] selects a
subset of variants whose main effects best predict the response. Where predictors are highly
correlated, the lasso tends to select one of a group of correlated predictors at random. In
contrast, the elastic net [92] selects groups of correlated variables. Model selection may also
be driven by external information, unrelated to any statistical properties of the data being
analysed. For example, the fused lasso [80, 79] uses ordering information, such as the position
of genomic features along a chromosome to select ‘adjacent’ features together.
Prior information on functional relationships between genetic predictors can also been used
to drive the selection of groups of variables. In the present context, information mapping genes
and SNPs to functional gene pathways has recently been used in sparse regression models for
pathway selection. Chen et al. [15] describe a method that uses a combination of lasso
and ridge regression to assess the significance of association between a candidate pathway
and a dichotomous (case-control) phenotype, and apply this method in a study of colon
cancer etiology. In contrast, Silver et al. [67] use group lasso penalised regression to select
pathways associated with a multivariate, quantitative brain-imaging phenotype characteristic
of structural change in the brains of patients with Alzheimer’s disease.
In identifying pathways associated with a trait of interest, a natural follow-up question is to
ask which SNPs and/or genes are driving pathway selection? We might further ask a related
question: can the use of prior information on putative gene interactions within pathways
increase power to identify causal SNPs, compared to alternative methods that disregard such
information? One way to answer these questions is by conducting a two-stage analysis, in
which we first identify important pathways, and then in a second step search for SNPs within
selected pathways [20, 21]. There are however a number of problems with this approach.
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Firstly, highlighted SNPs are then not necessarily those that were driving pathway selection
in the first step of the analysis. Secondly, the implicit (and reasonable) assumption is that
only a small number of SNPs in a pathway are driving pathway selection, so that ideally we
would prefer a model that has this assumption built in. The above considerations point to
the use of a ‘dual-level’ sparse regression model that imposes sparsity at both the pathway
and SNP level. Such a model would perform simultaneous pathway and SNP selection, with
the additional benefit of being simpler to implement.
A suitable sparse regression model enforcing the required dual-level sparsity is the sparse
group lasso (SGL) [69]. SGL is a comparatively recent development in sparse modelling, and
in simulations has been shown to accurately recover dual-level sparsity, in comparison to both
the group lasso and lasso [26, 69]. SGL has been used for the identification of rare variants
in a case-control study by grouping SNPs into genes [91]; for the identification of genomic
regions whose copy number variations have an impact on RNA expression levels [59]; and
to model geographical factors driving climate change [14]. SGL can be seen as fitting into a
wider class of structured-sparsity inducing models that use prior information on relationships
between predictors to enforce different sparsity patterns [90, 38, 41].
In the next section (Methods) we outline our method for sparse, pathways-driven SNP
selection, and demonstrate through simulation that the incorporation of prior information
mapping SNPs to gene pathways can boost the power to detect SNPs associated with a
quantitative trait. In the following section (Results), we describe an application study, in
which we investigate pathways, SNPs and genes associated with serum high-density lipopro-
tein cholesterol (HDLC) levels in two separate cohorts of Asian adults. HDLC refers to
the cholesterol carried by small lipoprotein molecules, so called high density lipoproteins
(HDLs). HDLs help remove the cholesterol aggregating in arteries, and are therefore pro-
tective against cardiovascular diseases [81]. Serum HDLC levels are genetically heritable
(h2 = 0.485) [57]. GWAS studies have now uncovered more than 100 HDLC associated loci
(see www.genome.gov/gwastudies, Hindorff et al. [32]). However, considering serum lipids as
a whole, variants so far identified account for only 25-30% of the genetic variance, highlighting
the limited power of current methodologies to detect hidden genetic factors [76].
Methods
This section is organised as follows. We begin by introducing the sparse group lasso (SGL)
model for pathways-driven SNP selection, along with an efficient estimation algorithm, for the
case of non-overlapping pathways. We then describe a simulation study illustrating superior
group (pathway) and variant (SNP) selection performance in the case that the true supporting
model is group-sparse. We continue by extending the previous model to the case of overlapping
pathways. In principle, we can then solve this model using the estimation algorithm described
for the non-overlapping case. However, we argue that this approach does not give us the
outcome we require. For this reason we describe a modified estimation algorithm that assumes
pathway independence, and demonstrate in a simulation study that this new algorithm is
able to identify the correct SNPs and pathways with improved sensitivity and specificity. We
complete this section with a description of a method to reduce bias in SNP and pathway
selection, together with a subsampling procedure to rank SNPs and pathways in order of
importance.
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The sparse group lasso model
We arrange the observed values for a univariate quantitative trait or phenotype, measured for
N unrelated individuals, in an (N × 1) response vector y. We assume minor allele counts for
P SNPs are recorded for all individuals, and denote by xij the minor allele count for SNP j
on individual i. These are arranged in an (N ×P ) genotype design matrix X. Phenotype and
genotype vectors are mean centred, and SNP genotypes are standardised to unit variance, so
that
∑
i x
2
ij = 1, for j = 1, . . . , P .
We assume that all P SNPs may be mapped to L groups or pathways, Gl ⊂ {1, . . . , P}, l =
1, . . . , L, and begin by considering the case where pathways are disjoint or non-overlapping,
so that Gl ∩ Gl′ = ∅ for any l 6= l′. We denote the vector of SNP regression coefficients
by β = (β1, . . . , βP ), and additionally denote the matrix containing all SNPs mapped to
pathway Gl by Xl = (xl1 ,xl2 , . . . ,xPl), where xj = (x1j , x2j , . . . , xNj)′, is the column vector
of observed SNP minor allele counts for SNP j, and Pl is the number of SNPs in Gl. We
denote the corresponding vector of SNP coefficients by βl = (βl1 , βl2 , . . . , βPl).
In general, where P is large, we expect only a small proportion of SNPs to be ‘causal’,
in the sense that they exhibit phenotypic effects. A key assumption in pathways analysis is
that these causal SNPs will tend to be enriched within a small set, C ⊂ {1, . . . , L}, of causal
pathways, with |C|  L, where |C| denotes the size (cardinality) of C. We denote the set of
causal SNPs mapping to pathway Gl by Sl, and make the further assumption that most SNPs
in a causal pathway are non-causal, so that |Sl| < Pl, where |Sl| denotes the size (cardinality)
of Sl. A suitable sparse regression model imposing the required, dual-level sparsity pattern
is the sparse group lasso (SGL). We illustrate the resulting causal SNP sparsity pattern in
Figure 1, and compare it to that generated by the group lasso (GL), a group-sparse model
that we used previously in a sparse regression method to identify gene pathways [66, 67].
G1 G2 GL
" 	   	  
G3
group	  lasso	  
" 	   	   sparse	  group	  
lasso	  
j = 1 2 3 P. . .
Figure 1: Sparsity patterns enforced by the group lasso and sparse group lasso. The set S ⊂ {1, . . . , P}
of causal SNPs influencing the phenotype are represented by boxes that are shaded grey. Causal SNPs
are assumed to occur within a set C ⊂ {1, . . . , L} of causal pathways, G1, . . . ,GL. Here C = {2, 3}.
The group lasso enforces sparsity at the group or pathway level only, whereas the sparse group lasso
additionally enforces sparsity at the SNP level.
With the SGL [69], sparse estimates for the SNP coefficient vector, β are given by
βˆSGL = arg min
β
{1
2
||y −Xβ||22 + (1− α)λ
L∑
l=1
wl||βl||2 + αλ||β||1
}
(1)
where λ (λ > 0) and α (|α| ≤ 1) are parameters controlling sparsity, and wl is a pathway
weighting parameter that may vary across pathways. (1) corresponds to an ordinary least
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squares (OLS) optimisation, but with two additional constraints on the coefficient vector, β,
that tend to shrink the size of β, relative to OLS estimates. One constraint imposes a group
lasso-type penalty on the size (`2 norm) of βl, l = 1, . . . , L. Depending on the values of λ, α
and wl, this penalty has the effect of setting multiple pathway SNP coefficient vectors, βˆl = 0,
thereby enforcing sparsity at the pathway level. Pathways with non-zero coefficient vectors
form the set Cˆ of ‘selected’ pathways, so that
Cˆ(λ, α) = {l : βˆl 6= 0}.
A second constraint imposes a lasso-type penalty on the size (`1 norm) of β. Depending on
the values of λ and α, for a selected pathway l ∈ Cˆ, this penalty has the effect of setting
multiple SNP coefficient vectors, βˆj = 0, j ⊂ Gl, thereby enforcing sparsity at the SNP level
within selected pathways. SNPs with non-zero coefficient vectors then form the set Sˆl of
selected SNPs in pathway l, so that
Sˆl(λ, α) = {j : βˆj 6= 0, j ∈ Gl}.
The set of all selected SNPs is given by
Sˆ =
⋃
l∈Cˆ
Sˆl.
The sparsity parameter λ controls the degree of sparsity in β, such that the number of
pathways and SNPs selected by the model increases as λ is reduced from a maximal value
λmax, above which βˆ = 0. The parameter α controls how the sparsity constraint is distributed
between the two penalties. When α = 0, (1) reduces to the group lasso, so that sparsity is
imposed only at the pathway level, and all SNPs within a selected pathway have non-zero
coefficients. When 0 < α < 1, solutions exhibit dual-level sparsity, such that as α approaches
0 from above, greater sparsity at the group level is encouraged over sparsity at the SNP level.
When α = 1, (1) reverts to the lasso, so that pathway information is ignored.
Model estimation
For the estimation of βˆSGL we proceed by noting that the optimisation (1) is convex, and
(in the case of non-overlapping groups) that the penalty is block-separable, so that we can
obtain a solution using block, or group-wise coordinate gradient descent (BCGD) [82]. A
detailed derivation of the estimation algorithm is given in the accompanying supplementary
information, Section A.
From (17) and (18), the criterion for selecting a pathway l is given by
||S(X′lrˆl, αλ)||2 > (1− α)λwl, (2)
and the criterion for selecting SNP j in selected pathway l by
||X ′j rˆl,j ||1 > αλ, (3)
where rˆl = rˆl −
∑
m 6=lXlβˆl and rˆl,j = rˆl −
∑
k 6=j Xkβˆk are respectively the pathway and
SNP partial residuals, obtained by regressing out the current estimated effects of all other
pathways and SNPs respectively. The complete algorithm for SGL estimation using BCGD
is presented in Box 1.
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Box 1 SGL-BCGD estimation algorithm
1. initialise β ← 0.
2. repeat: [pathway loop]
for pathway l = 1, 2, . . . , L:
if ||S(X′lrˆl, αλ)||2 ≤ (1− α)λwl
βl ← 0
else
repeat: [SNP loop]
for j = l1, . . . , lPl :
if βj = 0 :
Newton update β∗∗j ← βj using (24) and (22)
else:
Newton update β∗∗j ← βj using (21) and (22)
if f(β∗∗l ) > f(βl):
β∗∗j ←
β∗∗j +βj
2
βj ← β∗∗j
until convergence of βl [SNP loop]
until convergence of β [pathway loop]
3. βˆSGL ← β
SGL simulation study 1
We test the hypothesis that where causal SNPs are enriched in a given pathway, pathway-
driven SNP selection using SGL will outperform simple lasso selection that disregards pathway
information in a simple simulation study. We simulate P = 2500 genetic markers for N = 400
individuals. Marker frequencies for each SNP are sampled independently from a multinomial
distribution following a Hardy Weinberg equilibrium frequency distribution. SNP minor allele
frequencies are sampled from a uniform distribution U [0.1, 0.5]. SNPs are distributed equally
between 50 non-overlapping pathways, each containing 50 SNPs.
We then test each competing method over 500 Monte Carlo (MC) simulations. At each
simulation, a baseline univariate phenotype is sampled from N (10, 1). To generate genetic
effects, we randomly select 5 SNPs from a single, randomly selected pathway Gl, to form the
set S ⊂ Gl of causal SNPs. Genetic effects are then generated as described in Section C.
To enable a fair comparison between the two methods (SGL and lasso), we ensure that
both methods select the same number of SNPs at each simulation. We do this by first
obtaining the SGL solution, SˆSGL, with λ = 0.85λmax and α = 0.8, which ensures sparsity
at both the pathway and SNP level. We use a uniform pathway weighting vector w = 1. We
then compute the lasso solution using coordinate descent over a range of values for the lasso
regularisation penalty, λ, and choose the set
Sˆ lasso(λ′) such that |Sˆ lasso(λ′)| = |SˆSGL|
where |SˆSGL| is the number of SNPs previously selected by SGL, and |Sˆ lasso(λ′)| is the number
of SNPs selected by the lasso with λ = λ′. We measure performance as the mean power to
detect all 5 causal SNPs over 500 MC simulations, and test a range of genetic effect sizes
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Figure 2: SGL vs Lasso. Comparison of power to detect 5 causal SNPs. Each data point represents
mean power over 500 MC simulations. Left: Causal SNPs drawn from single causal pathway. Right:
Causal SNPs drawn at random.
(γ) (see C). In a follow up study, we compare the performance of the two methods in a
scenario in which pathways information is uninformative. For this we repeat the previous
simulations, but with 5 causal SNPs drawn at random from all 2500 SNPs, irrespective of
pathway membership. Results are presented in Figure 2.
Referring to Figure 2, we see that where causal SNPs are concentrated in a single causal
pathway (Figure 2 - left), SGL demonstrates greater power (and equivalently specificity, since
the total number of selected SNPs is constant), compared with the lasso, above a particular
effect size threshold (here γ ≈ 0.04). Where pathway information is not important, that is
causal SNPs are not enriched in any particular pathway (Figure 2 - right), SGL performs
poorly.
To gain a deeper understanding of what is happening here, we also consider the power
distributions across all 500 MC simulations corresponding to each point in the plots of Figure
2. These are illustrated in Figure 3. The top row of plots illustrates the case where causal
SNPs are drawn from a single causal pathway. Here we see that there is a marked difference
between the two distributions (SGL vs lasso). The lasso shows a smooth distribution in
power, with mean power increasing with effect size. In contrast, with SGL the distribution is
almost bimodal, with power typically either 0 or 1, depending on whether or not the correct
causal pathway is selected. This serves as an illustration of the advantage of pathway-driven
SNP selection for the detection of causal SNPs in the case that pathways are important. As
previously found by Zhou et al. [91] in the context of rare variants and gene selection, the
joint modelling of SNPs within groups gives rise to a relaxation of the penalty on individual
SNPs within selected groups, relative to the lasso. This can enable the detection of SNPs
with small effect size or low MAF that are missed by the lasso, which disregards pathways
information and treats all SNPs equally. Finally, where causal SNPs are not enriched in a
causal pathway (bottom row of Figure 3), as expected SGL performs poorly. In this case SGL
will only select a SNP where the combined effects of constituent SNPs in a pathway are large
enough to drive pathway selection.
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Figure 3: SGL vs Lasso. Distribution over 500 MC simulations of power to detect 5 causal SNPs.
Each plot represents the power distribution at a single data point in Figure 2. The power distribution
is discrete, since each method can identify 0, 1, 2, 3, 4 or 5 causal SNPs, with corresponding power
0, 0.2, 0.4, 0.6, 0.8 or 1.0. Top row: Causal SNPs drawn from single causal pathway. Bottom row:
Causal SNPs drawn at random.
The problem of overlapping pathways
The assumption that pathways are disjoint does not hold in practice, since genes and SNPs
may map to multiple pathways (see Figure 7). This means that typically Gl∩Gl′ 6= ∅ for some
l 6= l′. In the context of pathways-driven SNP selection using SGL, this has two important
implications. Firstly, the optimisation (1) is no longer separable into groups (pathways), so
that convergence using coordinate descent is no longer guaranteed [82]. Secondly, we wish to
be able to select pathways independently, and the SGL model as previously described does
not allow this . For example consider the case of an overlapping gene, that is a gene that
maps to more than one pathway. If a SNP mapping to this gene is selected in one pathway,
then it must be selected in each and every pathway containing the mapped gene, so that all
pathways mapping to the gene are selected. We instead want to admit the possibility that
the joint SNP effects in one pathway may be sufficient to allow pathway selection, while the
joint effects in another pathway containing some of the same SNPs do not pass the threshold
for pathway selection.
A solution to both these problems is obtained by duplicating SNP predictors in X, so that
SNPs belonging to more than one pathway can enter the model separately [39, 66]. The process
works as follows. An expanded design matrix is formed from the column-wise concatenation of
the L, (N ×Pl) sub-matrices, Xl, to form the expanded design matrix X∗ = [X1,X2, . . . ,XL]
of size (N×P ∗), where P ∗ = ∑l Pl. The corresponding P ∗×1 parameter vector, β∗, is formed
by joining the L, (Pl × 1) pathway parameter vectors, β∗l , so that β∗ = [β∗1 ′,β∗2 ′, . . . ,β∗L′]′.
Pathway mappings with SNP indices in the expanded variable space are reflected in updated
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Gl
Gk
Figure 4: Two pathways with partially overlapping causal SNPs. Causal SNPs (marked in grey) in
the set Sk overlap both pathways, so that Sk = Gk ∩ Gl. Additional causal SNPs, Sl ∩ \Sk, (marked
in purple) occur in pathway l only.
groups G∗1 , . . . ,G∗L. The SGL estimator (1), adapted to account for overlapping groups, is then
given by
βˆSGL∗ = arg min
β
{1
2
||y −X∗β∗||22 + (1− α)λ
L∑
l=1
wl||β∗l ||2 + αλ||β∗||1
}
. (4)
With this overlap expansion, the model is then able to perform pathway and SNP selection in
the way that we require, and the corresponding optimisation problem is amenable to solution
using the BCGD estimation algorithm described in Box 1. However, for the purpose of
pathways-driven SNP selection, the application of this algorithm presents a problem. This
arises from the replication of overlapping SNP predictors in each group, X∗l , that they occur.
Consider for example the simple situation where there are two pathways, G∗k ,G∗l , containing
sets of causal SNPs S∗k ⊆ G∗k and S∗l ⊆ G∗l respectively. Here the ∗ indicates that SNP indices
refer to the expanded variable space. We begin by assuming that S∗k and S∗l contain the same
SNPs, so that in the unexpanded variable space, Sk = Sl.
We then proceed with BCGD by first estimating β∗k. We assume that the correct SNPs
are selected, so that {βˆ∗j 6= 0 : j ∈ S∗k}, and βˆ∗j = 0 otherwise. For the estimation of
β∗l , the estimated effect
∑
j∈S∗k X
∗
j βˆ
∗
j , of these overlapping causal SNPs is removed from the
regression, through its incorporation in the block residual rˆ∗l = y −
∑
j∈S∗k X
∗
j βˆ
∗
j . Since no
other causal SNPs exist in pathway G∗l , X∗
′
l rˆ
∗
l = 0, so that the criterion for pathway selection,
||S(X∗′l rˆ∗l , αλ)||2 > (1− α)λwl (2) is not met. That is G∗l is not selected.
Now consider the case where additional, non-overlapping causal SNPs, possibly with
smaller effects, occur in G∗l , so that in the unexpanded variable space, Sk ⊂ Sl. In other
words, causal SNPs are partially overlapping (see Fig 4)1. During BCGD pathway G∗l is then
less likely to be selected by the model, than would be the case if there were no overlapping
SNPs, since once again the effects of overlapping causal SNPs, Sk ∩ Sl = Sk, are removed.
For pathways-driven SNP selection, we will argue that we instead require that SNPs are
selected in each and every pathway whose joint SNP effects pass a revised pathway selec-
tion threshold, irrespective of overlaps between pathways. This is equivalent to the previous
pathway selection criterion (2), but with the additional assumption that pathways are inde-
1This is the situation for example where multiple causal genes overlap both pathways, but one or more
additional causal genes occur in Gl.
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pendent, in the sense that they do not compete in the model estimation process. We describe
a revised estimation algorithm under the assumption of pathway independence below.
We justify the strong assumption of pathway independence with the following argument.
In reality, we expect that multiple pathways may simultaneously influence the phenotype, and
we also expect that many such pathways will overlap, for example through their containing one
or more ‘hub’ genes, that overlap multiple pathways [46, 48]. By considering each pathway
independently, we aim to maximise the sensitivity of our method to detect these variants
and pathways. In contrast, without the independence assumption, a competitive estimation
algorithm will tend to pick out one from each set of similar, overlapping pathways, and
miss potentially causal pathways and variants as a consequence. We illustrate this idea in
the simulation study in the following section. One potential concern is that by not allowing
pathways to compete against each other, specificity may be reduced, since too many pathways
and SNPs may be selected. We discuss the issue of specificity further in the context of results
from the simulation study.
A detailed derivation of the SGL model estimation algorithm under the independence
assumption is given in supplementary information, Section B. The main results are that the
pathway (2) and SNP (3) selection criteria become
||S(X′ly, αλ)||2 > (1− α)λwl, and
||X ′jy||1 > αλ (5)
respectively. The key difference is that partial derivatives rˆl and rˆl,j are replaced by y, that
is each pathway is regressed against the phenotype vector y. This means that there is no
block coordinate descent stage in the estimation, so that the revised algorithm utilises only
coordinate gradient descent within each selected pathway. For this reason we use the acronym
SGL-CGD for the revised algorithm, and SGL-BCGD for the previous algorithm using block
coordinate gradient descent. The new algorithm is described in Box 2.
Finally, we note that for SNP selection we are interested only in the set Sˆ of selected
SNPs in the unexpanded variable space, and not the set S∗ = {j∗ : β∗j 6= 0, j∗ ∈ {1, . . . , P ∗}}.
Since, under the independence assumption, the estimation of each β∗l does not depend on the
other estimates, β∗k, k 6= l, we do not need to record separate coefficient estimates for each
pathway in which a SNP is selected. Instead we need only record the set Sˆl, l ∈ Cˆ of SNPs
selected in each selected pathway. This has a useful practical implication, since we can avoid
the need for an expansion of X or β, and simply form the complete set of selected SNPs as
Sˆ =
⋃
l∈Cˆ
Sˆl.
SGL simulation study 2
We now explore some of the issues raised in the preceding section, specifically the potential
impact on pathway and SNP selection power and specificity of treating the pathways as
independent in the SGL estimation algorithm. We do this in a simulation study in which we
simulate overlapping pathways. The simulation scheme is specifically designed to highlight
differences in pathway and SNP selection with the independence assumption (using the SGL-
CGD estimation algorithm in Box 2) and without it (using the standard SGL estimation
algorithm in Box 1).
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Box 2 SGL-CGD estimation algorithm for overlapping pathways
1. initialise βˆ∗ ← 0.
2. for pathway l = 1, 2, . . . , L:
if ||S(X∗′l y, αλ)||2 ≤ (1− α)λwl
βˆ∗l ← 0
else
repeat: [CGD (SNP) loop]
for j = l1, . . . , lPl :
if βˆ∗j = 0 :
Newton update βˆ∗∗j ← βˆ∗j using (31) and (22)
else:
Newton update βˆ∗∗j ← βˆ∗j using (30) and (22)
if f(β∗∗l ) > f(β
∗
l ):
βˆ∗∗j ←
βˆ∗∗j +βˆ
∗
j
2
βˆ∗j ← βˆ∗∗j
until convergence
3. βˆSGL ← β∗
SNPs with variable MAF are simulated using the same procedure described in the previous
simulation study, but this time SNPs are mapped to 50 overlapping pathways, each containing
30 SNPs. Each pathway overlaps any adjacent (by pathway index) pathway by 10 SNPs. This
overlap scheme is illustrated in Figure 5 (a).
As before we consider a range of overall genetic effect sizes, γ. A total of 2000 MC
simulations are conducted for each effect size. At MC simulation z, we randomly select two
adjacent pathways, Gl,Gl+1 where l ∈ {1, . . . , 49}. From these two pathways we randomly
select 10 SNPs according to the scheme illustrated in Figure 5 (b). This ensures that causal
SNPs overlap a minimum of 1, and a maximum of 2 pathways, with Sz ⊂ (Gl ∩ \Gl−1) ∪
(Gl+1 ∩ \Gl+2). The true set of causal pathways, C, is then given by {l}, {l + 1} or {l, l + 1}
(although simulations where |C| = 1 will be extremely rare). Genetic effects on the phenotype
are generated as described previously (Section C).
SNP coefficients are estimated for each algorithm, SGL-BCGD and SGL-CGD, using the
same regularisation with λ = 0.85λmax and α = 0.85 for both.
The average number of pathways and SNPs selected by SGL-BCGD and SGL-CGD across
all 2000 MC simulations is reported in Table 1. As expected, for both models, the number of
selected variables (pathways or SNPs) increases with decreasing effect size, as the number of
pathways close to the selection threshold set by λmax increases.
For each model, at MC simulation z we record the pathway and SNP selection power,
|Cˆz ∩ Cz|/|Cz| and |Sˆz ∩ Sz|/|Sz| respectively. Since the number of selected variables can vary
slightly between the two models, we also record false positive rates (FPR) for pathway and
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Figure 5: SGL Simulation Study with overlapping pathways. (a): Illustration of pathway overlap
scheme. The are 30 SNPs in each pathway. Pathways Gl, (l = 1, . . . , 50) overlap each adjacent pathway
by 10 SNPs. (b): Causal SNPs from adjacent pathways, l, l+ 1 are randomly selected from the region
marked in purple, ensuring that SNPs in S overlap a maximum of two pathways.
Table 1: Simulation Study 2: Mean number of pathways and SNPs selected by each model at each
effect size, γ, across 2000 MC simulations.
γ
0.02 0.04 0.06 0.08 0.1 0.12
pathways SGL-CGD 5.8 5.9 5.4 4.8 3.9 3.2
SGL-BCGD 5.8 5.9 5.4 4.8 3.9 3.2
SNPs SGL-CGD 26.6 27.0 24.8 22.2 18.5 15.3
SGL-BCGD 28.8 29.3 26.7 23.6 19.4 15.8
12
SNP selection as |Cˆz ∩ \Cz|/|Cˆz| and |Sˆz ∩ \Sz|/|Sˆz| respectively.
The large possible variation in causal SNP distributions, causal SNP MAFs etc. make a
comparison of mean power and FPR between the two methods somewhat unsatisfactory. For
example, depending on effect size, a large number of simulations can have either very high,
or very low pathway and SNP selection power, masking subtle differences in performance
between the two methods. Since we are specifically interested in establishing the relative
performance of the two methods, we instead illustrate the number of simulations at which
one method outperforms the other across all 2000 MC simulations, and show this in Figure
6. In this figure, the number of simulations in which SGL-CGD outperforms SGL, i.e. where
SGL-CGD power > SGL-BCGD power, or SGL-CGD FPR < SGL-BCGD FPR, are shown
in green. Conversely, the number of simulations where SGL-BCGD outperforms SGL-CGD
are shown in red.
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Figure 6: SGL-CGD vs SGL-BCGD performance, measured across 2000 MC simulations. Top row:
Pathway selection performance. (Left) green bars indicate the number of MC simulations where SGL-
CGD has greater pathway selection power than SGL. Red bars indicate where SGL-BCGD has greater
power than SGL-CGD. (Right) green bars indicate the number of MC simulations where SGL-CGD
has a lower FPR than SGL. Red bars indicate the opposite. Bottom row: As above, but for SNP
selection performance.
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We first consider pathway selection performance (top row of Figure 6). For both methods,
the same number of pathways are selected on average, across all effect sizes (Table 1). At
low effect sizes, there is no difference in performance between the two methods for the large
majority of MC simulations, and where there is a difference, the two methods are evenly
balanced. As with SGL Simulation Study 1, this is the region (with γ ≤ 0.04) where pathway
selection fairs no better than chance. With γ > 0.04, SGL-CGD consistently outperforms
SGL, both in terms of pathway selection sensitivity and control of false positives (measured
by FPR).
To understand why, we turn to SNP selection performance (bottom row of Figure 6). At
small effect sizes (γ ≤ 0.04), in the small minority of simulations where the correct pathways
are identified, SGL-BCGD tends to demonstrate greater power than SGL-CGD (Figure 6
bottom left). However, this is at the expense of lower specificity (Figure 6 bottom right).
These difference are due to the slightly larger number of SNPs selected by SGL-BCGD (see
Table 1), which in turn is due to the ‘screening out’ of previously selected SNPs from the
adjacent causal pathway during BCGD, as described previously. This results in the selection
of a larger number of SNPs when any two overlapping pathways are selected by the model.
In the case where two causal pathways are selected, SNP selection power is then likely to be
higher, although at the expense of a greater number of false positives.
When pathway effects are just on the margin of detectability (γ = 0.06), SGL-CGD is more
often able to select both causal pathways, although this doesn’t translate into increased SNP
selection power. This is most likely because at this effect size neither model can detect SNPs
with low MAF, so that SGL-CGD is detecting the same (overlapping) SNPs in both causal
pathways. Note that once again SGL-BCGD typically has a higher FPR than SGL-CGD,
since more SNPs are selected from non-causal pathways.
As the effect size increases, the number of simulations in which SGL-CGD outperforms
SGL-BCGD for SNP selection power grows, paralleling the former method’s enhanced path-
way selection power. This is again a demonstration of the screening effect with SGL-BCGD
described previously. This means that SGL-CGD is more often able to select both causal
pathways, and to select additional causal SNPs that are missed by SGL. These additional
SNPs are likely to be those with lower MAF, for example, that are harder to detect with
SGL, once the effect of overlapping SNPs are screened out during estimation using BCGD.
Interestingly, as before SGL-CGD continues to exhibit lower false positive rates than SGL.
This suggests that, with the simulated data considered here, the independence assumption
offers better control of false positives by enabling the selection of causal SNPs in each and
every pathway to which they are mapped. In contrast, where causal SNPs are successively
screened out during the estimation using BCGD, too many SNPs with spurious effects are
selected.
The relative advantage of SGL-CGD over SGL-BCGD on all performance measures starts
to decrease around γ = 0.1, as SGL-BCGD becomes better able to detect all causal pathways
and SNPs, irrespective of the screening effect.
Pathway and SNP selection bias
One issue that must be addressed is the problem of selection bias, by which we mean the
tendency of SGL to favour the selection of particular pathways or SNPs under the null, where
no SNPs influence the phenotype. Possible biasing factors include variations in pathway size,
that is the number of SNPs mapping to a pathway, or varying patterns of SNP-SNP correla-
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tions and gene sizes. Common strategies for bias reduction include the use of dimensionality
reduction techniques and permutation methods [87, 35, 89, 16].
In earlier work we described an adaptive weight-tuning strategy, designed to reduce se-
lection bias in a group lasso-based pathway selection method [66]. This works by tuning the
pathway weight vector, w = (w1, w2, . . . , wL), so as to ensure that pathways are selected
with equal probability under the null. This strategy can be readily extended to the case of
dual-level sparsity with the SGL.
Our procedure rests on the observation that for pathway selection to be unbiased, each
pathway must have an equal chance of being selected. For a given α, and with λ tuned to
ensure that a single pathway is selected, pathway selection probabilities are then described
by a uniform distribution, Πl = 1/L, for l = 1, . . . , L. We proceed by calculating an empirical
pathway selection frequency distribution, Π∗(w), by determining which pathway will first be
selected by the model as λ is reduced from its maximal value, λmax, over multiple permutations
of the response, y. This process is described in detail in Supplementary Information D.
Our iterative weight tuning procedure then works by applying successive adjustments to
the pathway weight vector, w, so as to reduce the difference, dl = Π
∗
l (w) − Πl, between
the unbiased and empirical (biased) distributions for each pathway. At iteration τ , we com-
pute the empirical pathway selection probability distribution Π∗(w(τ)), determine dl for each
pathway, and then apply the following weight adjustment
w
(τ+1)
l = w
(τ)
l
[
1− sign(dl)(η − 1)L2d2l
]
0 < η < 1, l = 1, . . . , L.
The parameter η controls the maximum amount by which each wl can be reduced in a single
iteration, in the case that pathway l is selected with zero frequency. The square in the weight
adjustment factor ensures that large values of |dl| result in relatively large adjustments to wl.
Iterations continue until convergence, where
∑L
l=1 |dl| < .
Note that when multiple pathways are selected by the model, the expected pathway se-
lection frequency distribution under the null will not be uniform. This is because pathways
overlap, so that selection frequencies will reflect the complex distribution of overlapping genes,
as indeed will unbiased empirical selection frequencies. We have shown previously in exten-
sive simulations that this adaptive weight-tuning procedure gives rise to substantial gains in
sensitivity and specificity with regard to pathway selection [66].
Pathway, SNP and gene ranking
With most variable selection methods, a choice for the regularisation parameter, λ, must be
made, since this determines the number of variables selected by the model. Common strategies
include the use of cross validation to choose a λ value that minimises the prediction error
between training and test datasets [31]. One drawback of this approach is that it focuses on
optimising the size of the set, Cˆ, of selected pathways (more generally, selected variables) that
minimises the cross validated prediction error. Since the variables in Cˆ will vary across each
fold of the cross validation, this procedure is not in general a good means of establishing the
importance of a unique set of variables, and can give rise to the selection of too many variables
[85, 54]. For the lasso, alternative approaches, based on data subsampling or bootstrapping
have been shown to improve model consistency, in the sense that the correct model is selected
with a high probability [4, 54, 13]. These methods work by recording selected variables across
multiple subsamples of the data, and forming the final set of selected variables either as
the intersection of variables selected at each model fit, or by assessing variable selection
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frequencies. Examples of the use of such approaches can be found in a number of recent gene
mapping studies involving model selection using either the lasso or elastic net [17, 21, 56,
85]. Motivated by these ideas, we adopt a resampling strategy in which we calculate pathway,
gene and SNP selection frequencies by repeatedly fitting the model over B subsamples of
the data, at fixed values for α and λ. Each random subsample of size N/2 is drawn without
replacement. Our motivation here is to exploit knowledge of finite sample variability obtained
by subsampling, to achieve better estimates of a variable’s importance. With this approach,
which in some respects resembles the ‘pointwise stability selection’ strategy of Meinshausen
and Bu¨hlmann [54], selection frequencies provide a direct measure of confidence in the selected
pathways in a finite sample. This resampling strategy also allows us to rank pathways, genes
and SNPs in order of their strength of association with the phenotype, so that we expect the
true set of causal variables to achieve a high ranking, whereas non-causal variables will be
ranked low.
For pathway ranking, we denote the set of selected pathways at subsample b by
Cˆ(b) = {l : βˆ(b)l 6= 0} b = 1, . . . , B,
where βˆ
(b)
l is the estimated SNP coefficient vector for pathway l at subsample b. The selection
probability for pathway l measured across all B subsamples is then
pipathl =
1
B
B∑
b=1
I
(b)
l l = 1, . . . , L
where the indicator function, I
(b)
l = 1 if l ∈ Cˆ(b), and 0 otherwise. Pathways are ranked in
order of their selection probabilities, pipathl1 ≥, . . . ,≥ pi
path
lL
.
For SNP and gene ranking, we denote the set of SNPs selected at subsample b (in the
unexpanded variable space) by Sˆ(b), and further denote the set of selected genes to which
the SNPs in Sˆ(b) are mapped by φˆ(b) ⊂ Φ, where Φ = {1, . . . , G} is the set of gene indices
corresponding to all G mapped genes. Using the same strategy as for pathway ranking, we
obtain an expression for the selection probability of SNP j across B subsamples as
piSNPj =
1
B
B∑
b=1
J
(b)
j
where the indicator function, J
(b)
j = 1 if j ∈ Sˆ(b), and 0 otherwise. A similar expression for
the selection probability for gene g is
pigeneg =
1
B
B∑
b=1
K(b)g
where the indicator function, K
(b)
g = 1 if g ∈ φˆ(b), and 0 otherwise. SNPs and genes are then
ranked in order of their respective selection frequencies.
Results
Subjects, genotypes and phenotypes
The analysis is carried out using data from two separate cohorts of Asian adults. These
datasets have previously been used to search for novel variants associated with type 2 dia-
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betes mellitus (T2D) in Asian populations. The first (discovery) cohort is from the Singa-
pore Prospective Study Program, hereafter referred to as ‘SP2’, and the second (replication)
dataset is from the Singapore Malay Eye Study or ‘SiMES’. Detailed information on both
datasets can be found in Sim et al. [68], but we briefly outline some salient features here.
Both datasets comprise whole genome data for T2D cases and controls, genotyped on
the Illumina HumanHap 610 Quad array. For the present study we use controls only, since
variation in lipid levels between cases and controls can be greater than the variation within
controls alone. The use of both cases and controls in our analysis might then lead to a
confounded analysis, where any associations could be linked to T2D status or some other
spurious factor.
The SP2 dataset consists entirely of ethnic Chinese, and shows no evidence of population
stratification. The SiMES dataset comprises ethnic Malays, and shows some evidence of
cryptic relatedness between samples. For this reason, the first two principal components
of a PCA for population structure are used as covariates in our analysis of this dataset.
Again full details of the stratification analysis can be found in Sim et al. [68] and associated
supplementary information.
A summary of information pertaining to genotypes for each dataset, both before and after
imputation and pathway mapping, is given in Table 2, along with a list of phenotypes and
covariates.
Table 2: Genotype and phenotype information corresponding to the SP2 and SiMES datasets used in
the study.
SP2 Simes
Sample size N = 1, 040 N = 1, 099
Genotypes
Before imputation
SNPs available for analysis(1) 542, 297 557, 824
SNPs with missing genotypes(2) 152, 372 282, 549
Post imputation
SNPs available for analysis(3) 492, 639 515, 503
Phenotypes/covariates
quantitative trait (phenotype)(4) HDLC HDLC
covariates gender, age, age2, gender, age, age2,
BMI(5) BMI, PC1, PC2(6)
(1)after first round of quality control [68] and removal of monomorphic SNPs
(2)maximum 5% missing rate per SNP
(3)after imputation and removal of SNPs with MAF< 0.01
(4)mg/dL
(5)body mass index (kg/m2)
(6)principal components relating to cryptic relatedness
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Genotype imputation
After the initial round of quality control, genotypes for both datasets have a maximum SNP
missingness of 5%. Since our method cannot handle missing values, we perform ‘missing
holes’ SNP imputation, so that all missing SNP calls are estimated against a reference panel
of known haplotypes.
SNP imputation proceeds in two stages. First, imputation requires accurate estima-
tion of haplotypes from diploid genotypes (phasing). This is performed using SHAPEIT v1
(http://www.shapeit.fr). This uses a hidden Markov model to infer haplotypes from sample
genotypes using a map of known recombination rates across the genome [18]. The recombi-
nation map must correspond to genotype coordinates in the dataset to be imputed, so we
use recombination data from HapMap phase II, corresponding to genome build NCBI b36
(http://hapmap.ncbi.nlm.nih.gov/downloads/recombination/2008-03 rel22 B36/).
Following the primary phasing stage, SNP imputation is performed using IMPUTE v2.2.2
(http://mathgen.stats.ox.ac.uk/impute/impute v2.html). IMPUTE uses a reference panel
of known haplotypes to infer unobserved genotypes, given a set of observed sample haplo-
types [37]. The latest version (IMPUTE 2) uses an updated, efficient algorithm, so that a
custom reference panel can be used for each study haplotype, and for each region of the
genome, enabling the full range of reference information provided by HapMap3 [77] to be
used. Following IMPUTE 2 guidelines, we use HapMap3 reference data corresponding to
NCBI b36 (http://mathgen.stats.ox.ac.uk/impute/data download hapmap3 r2.html) which
includes haplotype data for 1,011 individuals from Africa, Asia, Europe and the Americas.
SNPs are imputed in 5MB chunks, using an effective population size (Ne) of 15,000, and a
buffer of 250kb to avoid edge effects, again as recommended for IMPUTE 2.
The phasing and imputation process is complex and computationally intensive. For this
reason we implement a pipeline in Python, with phasing and imputation for each chromosome
conducted in parallel across multiple nodes in a computing cluster. This enables full genome
imputation that would otherwise take days, to be completed in a matter of hours.
Pathway mapping
Pathways GWAS methods rely on prior information mapping SNPs to functional networks
or pathways. Since pathways are typically defined as groups of interacting genes, SNP to
pathway mapping is a two-part process, requiring the mapping of genes to pathways, and
of SNPs to genes. A consistent strategy for this mapping process has however yet to be
established, a situation compounded by a lack of agreement on what constitutes a pathway
in the first place [10].
The number and size of databases devoted to classifying genes into pathways is grow-
ing rapidly, as is the range and diversity of gene interactions considered (see for example
http://www.pathguide.org/). Databases such as those provided by KEGG (http://www.
genome.jp/kegg/pathway.html), Reactome (http://www.reactome.org/) and Biocarta (http:
//www.biocarta.com/) classify pathways across a number of functional domains, for exam-
ple apoptosis, cell adhesion or lipid metabolism; or crystallise current knowledge on specific
disease-related molecular reaction networks. Strategies for pathways database assembly range
from a fully-automated text-mining approach, to that of careful curation by experts. In-
evitably therefore, there is considerable variation between databases, in terms of both gene
coverage and consistency [71], so that the choice of database(s) will itself influence results in
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pathways GWAS.
The mapping of SNPs to genes adds a further layer of complexity, since although many
SNPs may occur within gene boundaries, on a typical GWAS array the vast majority of
SNPs will reside in inter-genic regions. In an attempt to include variants potentially residing
in functionally significant regions lying outside gene boundaries, SNPs may be mapped to
nearby genes using various distance thresholds. Various values for SNP to gene mapping
distances, measured in thousands of nucleotide base pairs (kb), have been suggested in the
literature, ranging from mapping SNPs to genes only if they fall within a specific gene, to the
attempt to encompass upstream promoters and enhancers by extending the range to 10, 20
or even 500kb and beyond [87, 20, 10]. This process is illustrated schematically in Figure 7.
Notable features of the SNP to pathway mapping process include the fact that genes (and
therefore SNPs) may map to more than one pathway, and also that many SNPs and genes do
not currently map to any known pathway [25].
	  
	  
pathways	  
genes	  
genotyped	  SNPs	  
	  
Figure 7: Schematic illustration of the SNP to pathway mapping process. (i) Genes (green circles)
are mapped to pathways using information on gene-gene interactions (top row), obtained from a gene
pathways database. Many genes do not map to any known pathway (unfilled circles). Also, some
genes may map to more than one pathway. (ii) Genes that map to a pathway are in turn mapped
to genotyped SNPs within a specified distance. Many SNPs cannot be mapped to a pathway since
they do not map to a mapped gene (unfilled squares). Note SNPs may map to more than one gene.
Some SNPs (orange squares) may map to more than one pathway, either because they map to multiple
genes belonging to different pathways, or because they map to a single gene that belongs to multiple
pathways.
Following imputation, SNPs for both datasets in the present study are mapped to KEGG
canonical pathways from the MSigDB database (http://www.broadinstitute.org/gsea/msigdb/
index.jsp). We exclude the largest KEGG pathway (by number of mapped SNPs), ‘Pathways
in Cancer’, since it is highly redundant in that it contains multiple other pathways as subsets.
Details of the pathway mapping process are given in Figures 8 and 9.
Note that there is a difference in the number of SNPs available for the pathway mapping
between the two datasets, and this results in a small discrepancy in the total number of
mapped genes (SP2: 4,734 mapped genes; SiMES: 4,751). However, both datasets map to all
185 KEGG pathways, and a large majority of mapped genes and SNPs overlap both datasets.
Detailed information on the pathway mapping process for the two datasets is presented in
Table 3.
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We perform pathways-driven SNP selection on both datasets, using the procedures described
in Methods. We present results for each dataset separately below.
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Figure 8: SP2 dataset. SNP to pathway mapping.
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Figure 9: SiMES dataset. SNP to pathway mapping.
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Table 3: Comparison of SNP and gene to pathway mappings for the SP2 and SiMES datasets.
SP2 SiMES
Total SNPs mapping to pathways 75,389 78,933
Total SNPs mapping to pathways in both datasets (intersection) 74,864
Total mapped genes 4,734 4,751
Total genes mapping to pathways in both datasets (intersection) 4,726
Total mapped pathways 185 185
Minimum number of genes mapping to single pathway 11 11
Maximum number of genes mapping to single pathway 63 63
Minimum number of SNPs mapping to single pathway 66 67
Maximum number of SNPs mapping to single pathway 5,759 6,058
Minimum number of pathways mapping to a single SNP 1 1
Maximum number of pathways mapping to a single SNP 45 45
SP2 Analysis
For the SP2 dataset we consider two separate scenarios for the regularisation parameters λ
and α. For the two scenarios we set the sparsity parameter, λ = 0.95λmax, but consider
two values for α, namely α = 0.95, 0.85. We test each scenario over 1000 N/2 subsamples.
We also compare the resulting pathway and SNP selection frequency distributions with null
distributions, again over 1000 N/2 subsamples, but with phenotype labels permuted, so that
no SNPs can influence the phenotype.
The parameter α controls how the regularisation penalty is distributed between the `2
(pathway) and `1 (SNP) norms of the coefficient vector. Each scenario therefore entails
different numbers of selected pathways and SNPs, and this information is presented in Table
4.
Table 4: Separate combinations of regularisation parameters, λ and α used for analysis of the SP2
dataset. For each λ, α combination, the mean (±SD) number of selected pathways and SNPs across
all 1000 subsamples is reported.
λ = 0.95λmax
α = 0.85 α = 0.95
empirical
selected pathways 7.9± 6.1 4.8± 4.1
selected SNPs 1551± 1294 160± 185
null
selected pathways 9.1± 7.2 5.0± 4.55
selected SNPs 1656± 1401 155± 194
Comparisons of empirical and null pathway selection frequency distributions for each
scenario are presented in Figure 10. The same comparisons for SNP selection frequencies are
presented in Figure 11. In these plots, null distributions (coloured blue) are ordered along
the x-axis according to their corresponding ranked empirical selection frequencies (marked in
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red). This is to help visualise any potential biases that may be influencing variable selection
(see below).
To interpret these results, we begin by noting from Table 4 that many more SNPs are
selected with α = 0.85, resulting in higher SNP selection frequencies, compared to those
obtained with α = 0.95 (see Figure 11). This is as expected, since a lower value for α implies
a reduced `1 penalty on the SNP coefficient vector, resulting in more SNPs being selected.
Perhaps surprisingly, given that the `2 group penalty (1 − α)λ is increased, the number of
selected pathways is also greater. This must reflect the reduced `1 penalty, which allows a
greater number of SNPs to contribute to a putative selected pathway’s coefficient vector. This
in turn increases the number of pathways that pass the threshold for selection.
This raises the question of what might be considered to be an optimal choice for the
regularisation-distributional parameter α, since different assumptions about the number of
SNPs potentially influencing the phenotype may affect the resulting pathway and SNP rank-
ings. To answer this, we turn our attention to the pathway and SNP selection frequency
distributions for each α value in Figures 10 and 11. At the lower value of α = 0.85 (top plots
in Figures 10 and 11), empirical pathway and SNP selection frequency distributions appear
to be biased, in the sense that there is a suggestion that pathways and SNPs with the highest
empirical selection frequencies also tend to be selected with a higher frequency under the null,
where there is no association between genotype and phenotype. This relationship appears to
be diminished with α = 0.95, when fewer SNPs are selected by the model. We investigate
this further by plotting empirical vs. null selection frequencies as a sequence of scatter plots
in Figure 12, and we report Pearson correlation coefficients and p-values for these in Table 5.
Table 5: SP2 dataset: Pearson correlation coefficients (r)and p-values for the data plotted in Figure
12. n denotes the number of predictors considered. For SNPs, coefficients describe correlations for all
predictors selected with nonzero empirical selection frequencies only, since a large number of SNPs are
not selected by the model at any subsample.
α = 0.85 α = 0.95
n r p-value n r p-value
pathways 185 0.66 1.3× 10−24 185 0.26 2.9× 10−4
SNPs 62, 965 0.37 0 30, 027 0.11 1.2× 10−84
These provide further evidence of increased correlation between empirical and null selec-
tion frequency distributions at the lower α value for both pathways and SNPs, again sug-
gesting increased bias in the empirical results, in the sense that certain pathways and SNPs
tend to be selected with a higher frequency, irrespective of whether or not a true signal may
be present. Further qualitative evidence of reduced bias with α = 0.95 is suggested by the
clearer separation of empirical and null distributions at the higher α value in Figures 10 and
11. For example, the maximum empirical pathway selection frequency is reduced by a factor
of 0.29 (0.35 to 0.25) as α is increased from 0.85 to 0.95, whereas the maximum pathway
selection frequency under the null is reduced by a factor of 0.81 (0.29 to 0.054). Similarly for
SNPs, the maximum empirical SNP selection frequency is reduced by a factor of 0.37 (0.52 to
0.33), whereas the maximum SNP selection frequency under the null is reduced by a factor
of 0.9 (0.11 to 0.011).
The increased bias with α = 0.85 is most likely due to the selection of too many SNPs,
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Figure 10: Empirical and null pathway selection frequency distributions for all 185 KEGG pathways
with the SP2 dataset. For each scenario, pathways are ranked along the x-axis in order of their
empirical pathway selection frequency, pipathl1 >, . . . , > pi
path
lL
. (a) α = 0.85. (b) α = 0.95.
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(a)
(b)
Figure 11: Empirical and null SNP selection frequency distributions with the SP2 dataset. For each
scenario, SNPs are ranked along the x-axis in order of their empirical pathway selection frequency,
piSNPj1 > pi
SNP
j2
> . . .. (a) α = 0.85. (b) α = 0.95. Note fewer SNPs are selected with nonzero empirical
selection frequency with α = 0.95, so that the x-axis range in (b) is reduced.
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Figure 12: SP2 dataset: Scatter plots comparing empirical and null selection frequencies presented in
Figures 10 and 11. (a) and (b): Pathway selection frequencies with α = 0.85, 0.95 respectively. (c) and
(d): SNP selection frequencies for the same α values. For clarity, SNP selection frequencies are plotted
for the top 1000 SNPs (by empirical selection frequency) only. Corresponding correlation coefficients
(for all ranked SNPs) are presented in Table 5. Note that pathway and SNP selection frequencies are
much higher at the lower α value (left hand plots), since many more variables are selected (see Table
4.)
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in the sense that many selected SNPs do not exhibit real phenotypic effects. These extra
SNPs effectively add noise to the model, in the form of multiple weak, spurious signals. This
in turn will add bias to the resulting selection frequency distributions, tending to favour, for
example, SNPs that overlap multiple pathways, and the pathways that contain them. As α
is increased, we would expect this biasing effect to be reduced, until a point where too few
SNPs are selected, when there is then a risk that some of the true signal may be lost.
Note that the reduced but still significant correlations between empirical and null selection
frequency distributions at α = 0.95 in Table 5 are not unexpected. These may reflect the
complex overlap structure between pathways, meaning that pathways (and associated SNPs)
with a relatively high degree of overlap with other pathways, due for example to the presence
of so called ‘hub genes’, are more likely to harbour true signals, as well as spurious ones [48,
11, 42].
Taking all the above into consideration, we choose to report results with α = 0.95, where
there is less evidence of bias due to the selection of too many SNPs. The top 30 pathways,
ranked by selection frequency are presented in Table 6, and the top 30 ranked SNPs, together
with corresponding genes to which they are mapped are presented in Table 7. Versions of
these tables extending to lower ranks are provided as supplementary information.
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Table 7: SP2 dataset: Top 30 SNPs and genes, respectively ranked by SNP and gene selection fre-
quency. Genes falling in the top 30 ranks of the consensus gene set, Ψgene244 , obtained by comparing
gene ranking results from both SP2 and SiMES datasets (see Table 13), are marked with a ∗.
SNP RANKING GENE RANKING
Rank SNP piSNP Mapped gene(s) Gene pigene # mapped SNPs
1 rs2257167 0.33 IFNAR1 IFNAR1 0.33 11
2 rs2254315 0.32 IFNAR1 IL12B 0.30 9
3 rs1041868 0.32 IFNAR1 PIAS2 0.30 7
4 rs7364085 0.31 IFNAR1 TIRAP 0.22 5
5 rs2850021 0.31 IFNAR1 RAC1 0.21 10
6 rs2253413 0.31 IFNAR1 LAMA2 ∗ 0.19 111
7 rs2243590 0.31 IFNAR1 ADCY2 ∗ 0.19 94
8 rs2834204 0.31 IFNAR1 PIK3R1 0.19 28
9 rs3181224 0.30 IL12B PARK2 0.19 460
10 rs512868 0.28 PIAS2 IL2RA 0.19 55
11 rs641366 0.24 PIAS2 PRKCA∗ 0.19 123
12 rs2032215 0.22 PIAS2 ITGB8 0.18 27
13 rs8177375 0.22 TIRAP TCF7L1 0.18 55
14 rs10893493 0.21 TIRAP CD80 ∗ 0.18 21
15 rs4890341 0.20 PIAS2 GRIN3A 0.18 60
16 rs2303361 0.19 RAC1 PRKCB∗ 0.18 83
17 rs7873495 0.17 GRIN3A PPP3R2 CACNA1C ∗ 0.17 180
18 rs1323653 0.17 IL2RA TGFB3 0.16 7
19 rs11762117 0.16 ITGB8 PRKACB 0.16 16
20 rs3807955 0.16 ITGB8 KRAS∗ 0.16 21
21 rs10462842 0.15 ADCY2 VAV3 0.16 97
22 rs10215885 0.15 ITGB8 IL5RA 0.15 38
23 rs3807936 0.15 ITGB8 ITGA1 ∗ 0.15 77
24 rs530205 0.15 PIAS2 VAV2 ∗ 0.15 85
25 rs3823974 0.15 ITGB8 EGFR∗ 0.14 61
26 rs2074425 0.15 ITGB8 TPO 0.14 50
27 rs6725799 0.15 TCF7L1 CACNA2D3 ∗ 0.14 283
28 rs2301727 0.15 ITGB8 RYR2 ∗ 0.14 214
29 rs10486391 0.14 ITGB8 NOS1 0.14 49
30 rs3779505 0.14 ITGB8 RFWD2 0.13 31
28
SiMES Analysis
For the replication SiMES dataset, we repeat the above analysis design, but consider only
the ‘low bias’ scenario where λ = 0.95λmax and α = 0.95. Once again we test each scenario
over 1000 N/2 subsamples, and compare the resulting pathway and SNP selection frequency
distributions with null distributions generated over 1000 N/2 subsamples with phenotype
labels permuted. Pathway and SNP selection frequency distributions are presented in Figure
14. An investigation of pathway and SNP selection bias is presented in the form of scatter plots
illustrating potential correlation between empirical and null selection frequencies in Figure 13,
with corresponding Pearson correlation coefficients and p-values presented in Table 8. The
top 30 ranked pathways, and SNPs and genes are presented in Tables 9 and 10 respectively.
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Figure 13: SiMES dataset: Scatter plots comparing empirical and null pathway (left) and SNP (right)
selection frequencies presented in Figure 14. For clarity, SNP selection frequencies are plotted for the
top 1000 SNPs (by empirical selection frequency) only.
Table 8: SiMES dataset: Pearson correlation coefficients (r)and p-values for the data plotted in Figure
13. n denotes the number of predictors considered. For SNPs, coefficients describe correlations for all
predictors selected with nonzero empirical selection frequencies only, since a large number of SNPs are
not selected by the model at any subsample.
n r p-value
pathways 185 −0.094 0.20
SNPs 20, 006 0.058 2.63× 10−16
29
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Figure 14: Empirical and null pathway (top) and SNP (bottom) selection frequency distributions
for the SiMES dataset. α = 0.95. For both empirical (red) and null (blue) distributions, variables
(pathways and SNPs) are ranked along the x-axis in order of their empirical selection frequencies.
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Table 10: SiMES dataset: Top 30 SNPs and genes, respectively ranked by SNP and gene selection
frequency. Genes falling in the top 30 ranks of the consensus gene set, Ψgene244 , obtained by comparing
gene ranking results from both SP2 and SiMES datasets (see Table 13), are marked with a ∗.
SNP RANKING GENE RANKING
Rank SNP piSNP Mapped gene(s) Gene pigene # mapped SNPs
1 rs2636698 0.31 PPA2 PPA2 0.31 16
2 rs2726503 0.31 PPA2 PDSS2 0.26 59
3 rs2713829 0.31 PPA2 GABARAPL1 0.18 11
4 rs2636726 0.31 PPA2 ATP6V0A4 0.15 35
5 rs2713834 0.31 PPA2 ITGB1 0.13 14
6 rs2726471 0.31 PPA2 CACNA1C ∗ 0.11 186
7 rs2636713 0.31 PPA2 PRKCB∗ 0.11 84
8 rs2726516 0.31 PPA2 FYN 0.11 46
9 rs2636739 0.31 PPA2 BCL2 ∗ 0.10 61
10 rs2713861 0.31 PPA2 PAK7 ∗ 0.10 127
11 rs2636751 0.31 PPA2 DGKB 0.10 233
12 rs2298733 0.30 PPA2 LAMA2 ∗ 0.10 118
13 rs6568474 0.26 PDSS2 NDUFA4 0.10 7
14 rs9386622 0.26 PDSS2 DGKH 0.10 70
15 rs6924886 0.26 PDSS2 ADCY2 ∗ 0.09 104
16 rs759440 0.25 PDSS2 LIPC 0.09 69
17 rs11759792 0.23 PDSS2 SLC8A1 ∗ 0.09 240
18 rs10457161 0.20 PDSS2 EGFR∗ 0.09 74
19 rs12821011 0.18 GABARAPL1 PRKAG2 0.09 118
20 rs11053685 0.18 GABARAPL1 CACNA1D 0.09 83
21 rs4764324 0.18 GABARAPL1 ITGA11 ∗ 0.09 63
22 rs4764327 0.18 GABARAPL1 IGF1R∗ 0.09 100
23 rs9373924 0.18 PDSS2 SDHC 0.09 9
24 rs10845074 0.18 GABARAPL1 CACNA2D3 ∗ 0.08 294
25 rs9320215 0.17 PDSS2 RYR2 ∗ 0.08 221
26 rs10845073 0.17 GABARAPL1 ITGA1 ∗ 0.08 77
27 rs4946826 0.16 PDSS2 ALDH7A1 0.08 23
28 rs6938393 0.15 PDSS2 MGST3 ∗ 0.08 40
29 rs13202332 0.13 PDSS2 ALDH2 0.08 12
30 rs9480754 0.13 PDSS2 SDHB 0.08 13
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Comparison of ranked pathway lists
We now consider the problem of comparing rankings (pathways, genes and SNPs) obtained for
each dataset. To do this we require some measure of distance between each pair of lists. Ideally
this measure should place more emphasis on differences between highly-ranked variables, since
we expect the association signal, and hence agreement between the ranked lists, to be strongest
there. By the same reasoning, we expect there to be little or no agreement between variables
at lower rankings, where selection frequencies are low. Indeed a consideration of empirical
and null selection frequency distributions (Figures 10 and 14, top) suggests that only the very
top ranked variables are likely to reflect any true signal, so that we would additionally like
our distance metric to be able to accommodate consideration of the top-k variables only, with
k < p, where p is the total number of variables ranked in either dataset. One complication
with top-k lists is that they are partial, in the sense that unlike complete (k = p) lists, a
variable may occur in one list, but not the other.
In order to consider this problem, we introduce the following notation. We denote the
complete set of ranked predictors by L = {1, . . . , p}, and begin by assuming that all variables
are ranked in both datasets. We denote the rank of each variable in list 1 by τ(i), i = 1, . . . , p,
so that τ(5) = 1 if variable 5 is ranked first and so on. The corresponding ranks for list 2 are
denoted by σ(i), i = 1, . . . , p. A suitable metric describing the distance between two top-k
rankings is the Canberra distance [44],
Ca(k, τ, σ) =
p∑
i=1
|min{τ(i), k + 1} −min{σ(i), k + 1}|
min{τ(i), k + 1}+ min{σ(i), k + 1} . (6)
This has the properties that we require, in that the denominator ensures more emphasis is
placed on differences in the ranks of highly ranked variables in either dataset. Furthermore,
this distance measure allows comparisons between partial, top-k lists, since a variable occur-
ring in one top-k list but not the other is assigned a ranking of k + 1 in the list from which
it is missing. Note also that a variable i that is not in either of the top-k ranks, that is
τ(i), σ(i) > k, makes no contribution to Ca(k, τ, σ).
In order to gauge the extent to which the distance measure (6) differs from that expected
between two random lists, we require a value for the expected Canberra distance between two
random lists, which we denote E[Ca(k, p)]. Jurman et al. [44] derive an expression for this
quantity, and we use this to compute the normalised Canberra distance,
Ca∗(k, τ, σ) =
Ca(k, τ, σ)
E[Ca(k, p)]
. (7)
Note that this has a lower bound of 0, corresponding to exact agreement between the lists.
For two random lists, the upper bound will generally be close to 1, although it can exceed
1, particularly for small k, since the expected value for random lists is not necessarily the
highest value.
We illustrate the variation of the normalised Canberra distance (7) between SP2 and
SiMES pathway rankings in the left hand plot in Figure 15 (blue curve). We consider all
possible top-k lists, k = 1, . . . , 185 since all 185 pathways are ranked in both datasets. In the
same plot, we also show
Ca∗pi(k, τ, σ) =
1
Z
Z∑
pi=1
Ca(k, τ, σpi)
E[Ca(k, p)]
k = 1, . . . , 185 (8)
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obtained by comparing empirical SP2 rankings (τ) against Z = 10, 000 permutations of the
SiMES pathway rankings, σpi, pi = 1, . . . , 10, 000 (green curve). This latter curve confirms
that the expected value, E[Ca(k, p)], is indeed a good measure of Ca in the random case
where there is no agreement between rankings.
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Figure 15: Comparison of top-k SP2 and SiMES pathway rankings. Left hand plot: Variation of
normalised Canberra distance, Ca∗ with k (7) (blue curve). Corresponding mean values over Z =
10, 000 permutations of SiMES rankings (8) (green curve). Right hand plot: FDR q-values (blue
curve). Dotted green line shows the threshold for FDR control at the 5% level.
Using the same permuted rankings, σpi, we next test the null hypothesis that the observed
normalised Canberra distance, Ca∗(k, τ, σ), is not significantly different from that between τ
and a random list σpi, by computing a p-value as
p∗(k) =
1
Z
Z∑
pi=1
ICa∗(k,τ,σ)≤Ca∗(k,τ,σpi),
for k = 1, . . . , 185. We then obtain FDR q-values using the Benjamini-Hochberg procedure
[5] and illustrate these for each k in the right hand plot of Figure 15. FDR is controlled at
a nominal 5% level for 19 ≤ k ≤ 71, indicating that the distance between the top-k pathway
rankings for both datasets is significantly different from the random ranking case for a wide
range of possible values of k. The distance Ca∗ between SP2 and SiMES pathway rankings
however attains its minimum value when k = 25 with q(25) = 0.037, so that on this measure,
the two pathway rankings are in closest agreement when we consider the top 25 pathways in
each ranked list only. Some intuitive understanding of why this might be so can be gained by
considering the empirical vs. null pathway selection frequency distributions for each dataset
in Figures 10 (b) and 14 (top). Here we see that the separation between empirical and null
selection frequencies is most clear for values of k below around 30 for SP2, and around 15 for
SiMES.
If we assume that the two pathway rankings are indeed in closest agreement when k = 25,
then one means of obtaining a consensus set of important pathways is to consider their
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intersection,
Ψpath25 = {i : τ−1(i) ≤ 25} ∩ {j : σ−1(j) ≤ 25},
from which we can obtain a set of average rankings as
ψpath25 =
{τ(z) + σ(z)
2
: z ∈ Ψpath25
}
.
Both the intersection set, Ψpath25 , and ordered average rankings, ψ
path
25 for the two datasets
under consideration are shown in Table 11. We additionally mark the consensus set Ψ25path
with asterisks in Tables 6 and 9.
Table 11: Consensus set of pathways, Ψpath25 , for SP2 and SiMES datasets with k = 25. Consensus
pathways are ordered by their average rankings in ψpath25 .
Pathway Average rank (ψpath25 )
Dilated Cardiomyopathy 4.5
Hypertrophic Cardiomyopathy 7.5
T Cell Receptor Signaling Pathway 11.0
Terpenoid Backbone Biosynthesis 11.0
Arrhythmogenic Right Ventricular Cardiomyopathy 12.0
Ribosome 13.0
Ppar Signaling Pathway 18.5
Comparison of ranked gene and SNP lists
A number of factors complicate the comparison of ranked gene and SNP lists across both
datasets. Firstly, sets of mapped SNPs and genes differ slightly between the two datasets
(see Table 2). Secondly, even if we consider only those variables mapped in both datasets,
different, though overlapping sets of variables are ranked in each. Thirdly, ranked variables are
not independent [44]. For example, genes may be grouped into pathways, so that a reordering
of genes within a pathway might be considered less significant than a reordering of genes
mapping to different pathways. Similarly a reordering of SNPs mapping to a single gene
might be considered less significant than a reordering of SNPs mapping to different genes.
In order to compute a distance measure between pairs or ranked lists, we therefore make
two simplifying assumptions. First, we consider only variables ranked in one or both datasets.
This seems reasonable, since we can necessarily only compile a distance measure from variables
that are ranked in one or both datasets. Second, we assume that variables are independent.
This makes our distance measure conservative, in the sense that it will treat all reordering of
SNPs or genes equally, irrespective of any potential functional relationship between them.
With these assumptions in mind, we begin by denoting the set of all p∗ variables (genes
or SNPs) that are ranked in either dataset by L = {1, . . . , p∗}. We further denote the
corresponding sets of ranked variables for SP2 and SiMES datasets by Lτ and Lσ respectively.
We then have the following set relations: Lτ ,Lσ ⊂ L; Lτ 6= Lσ; and |Lτ | 6= |Lσ|.
We now extend the previous Canberra distance measure to encompass the above set
relations. We begin, as before, by defining two ranked lists corresponding to the rankings
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of all the variables in L for each dataset, although this time we must account for the fact
that not all variables in L are ranked in both. We denote SP2 rankings by τ(i), i = 1, . . . , p∗,
where τ(i) is the rank of variable i if i ∈ Lτ , and τ(i) = p∗ otherwise. SiMES rankings are
defined in the same way, and denoted by σ(i), i = 1, . . . , p∗.
Applying this revised ranking scheme, we can then define a top-k normalised Canberra
distance (6) as
Ca∗(k, τ, σ) =
Ca(k, τ, σ)
E[Ca(k, p∗)]
. (9)
for any k ≤ min{|Lτ |, |Lσ|}. The restriction on k follows from the fact that we cannot distin-
guish between top-k rankings for all k > min{|Lτ |, |Lσ|}.
Gene rankings
Information summarising the relationship between the two ranked lists of genes is given in
Table 12.
Table 12: Summary of genes analysed and ranked in SP2 and SiMES datasets.
SP2 SiMES
number of genes mapped to pathways 4,734 4,751
number of genes mapping to both datasets 4,726
number of ranked genes (|Lτ |, |Lσ|) 3,430 2,815
number of genes ranked in either dataset (p∗) 3,913
number of genes ranked in both datasets (|Lτ | ∩ |Lσ|) 2,332
We consider normalised Canberra distances, Ca∗(k, τ, σ), for k = 1, . . . , 500 only, and plot
these in Figure 16 (left, blue curve), along with Ca∗pi(k, τ, σ) (8) for Z = 10, 000 permutations
of the SiMES pathway rankings, σpi, pi = 1, . . . , 10, 000 (green curve). Once again this latter
curve confirms that the expected value, E[Ca(k, p∗)], is indeed a good measure of Ca in the
random case where there is no agreement between rankings. We also plot FDR q-values using
the same procedure as described previously for pathways. FDR is controlled at a nominal 5%
level for all k > 13 in the region tested (1 ≤ k ≤ 500). The distance Ca∗ between SP2 and
SiMES pathway rankings attains its minimum value when k = 244, so that on this measure,
the two gene rankings are in closest agreement when we consider the top 244 pathways in
each ranked list only.
Following the same strategy as implemented for pathways, we then form the consensus
set, Ψgene244 , and average rankings ψ
gene
244 . The consensus set contains 84 genes, and we list the
top 30 genes ordered by their average rank in the two datasets, in Table 13.
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Table 13: Top 30 consensus genes ordered by their average rank, ψgene244 .
Rank Gene Average rank (ψgene244 )
1 LAMA2 9.0
2 ADCY2 11.0
3 CACNA1C 11.5
4 PRKCB 11.5
5 PRKCA 21.0
6 EGFR 21.5
7 ITGA1 24.5
8 CACNA2D3 25.5
9 RYR2 26.5
10 IGF1R 30.5
11 PAK7 36.5
12 ADCY8 37.5
13 VAV2 41.0
14 SLC8A1 41.5
15 CACNB2 42.5
16 CACNA2D1 43.0
17 ITGA9 44.0
18 KRAS 47.5
19 MAPK10 50.5
20 CACNA1S 51.0
21 VAV3 54.0
22 PLCG2 55.5
23 BCL2 57.0
24 CD80 60.0
25 ITGA11 60.5
26 CTNNA2 61.0
27 ALDH1B1 61.5
28 MGST3 63.0
29 NEDD4L 63.0
30 PRKAG2 66.0
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Figure 16: Comparison of top-k SP2 and SiMES gene rankings, for k = 1, . . . , 500. Left hand plot:
Variation of normalised Canberra distance, Ca∗ with k (9) (blue curve), and corresponding mean
values over 10,000 permutations of SiMES rankings (8) (green curve). Right hand plot: FDR q-values
(blue curve). Dotted green line shows the threshold for FDR control at the 5% level.
SNP rankings
Information summarising the relationship between the two ranked lists of SNPs is given
in Table 14. In contrast to both pathway and gene rankings, it is apparent that relatively
few ranked SNPs overlap both datasets – 8,151 out of 41,452 SNPs that are ranked in either
dataset. This results in values for Ca∗(k) that are close to 1, corresponding to the random
list case, over a wide range of possible values for k (data not shown).
For this reason, we compute a simple summary measure
ψSNP =
{τ(j) + σ(j)
2
: j ∈ Lτ ∩ Lσ
}
(10)
and report only the top ranking SNPs using this measure in Table 15.
Table 14: Summary of SNPs analysed and ranked in SP2 and SiMES datasets.
SP2 SiMES
number of SNPs mapped to pathways 75,389 78,933
number of SNPs mapping to both datasets 74,864
number of ranked SNPs (|Lτ |, |Lσ|) 30,027 20,006
number of SNPs ranked in either dataset (p∗) 41,452
number of SNPs ranked in both datasets (|Lτ | ∩ |Lσ|) 8,581
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Table 15: Top 30 SNPs ranked in both SP2 and SiMES datasets, ranked in order of mean ranking,
rank SNP ψSNP mapped gene(s)
1 rs897799 133.0 COX6B2 IL11
2 rs2126953 203.0 ITGA1
3 rs7714110 213.0 ADCY2
4 rs6924886 274.5 PDSS2
5 rs2447867 275.5 ITGA1
6 rs9386622 283.0 PDSS2
7 rs6568474 283.5 PDSS2
8 rs10446497 349.5 PAK2
9 rs6583177 385.5 PAK2
10 rs4765961 429.0 CACNA1C
11 rs759440 457.0 PDSS2
12 rs10457161 465.0 PDSS2
13 rs10462842 479.5 ADCY2
14 rs9373932 529.0 PDSS2
15 rs12206487 532.0 LAMA2
16 rs743567 543.0 MYH7
17 rs12472674 543.0 CTNNA2
18 rs11759792 557.5 PDSS2
19 rs9373924 566.0 PDSS2
20 rs319070 623.0 PDSS2
21 rs751877 630.0 ADCY4 LTB4R RIPK3
22 rs2047698 714.0 PDGFD
23 rs4804505 727.5 PDE4A KEAP1
24 rs12672417 764.0 SMURF1
25 rs7766689 800.5 LAMA2
26 rs157694 860.0 MAP3K7
27 rs554192 878.0 NEDD4L
28 rs2746543 896.5 SDHB
29 rs742257 942.0 LAMB3
30 rs1798619 944.5 PAK2
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Discussion
We have outlined a method for the detection of pathways, SNPs and genes associated with a
quantitative trait. Our method uses a sparse regression model, the sparse group lasso, that
enforces sparsity at the pathway and SNP level. As well as identifying important pathways,
this approach is designed to maximise the power to detect causal SNPs, possibly of low effect
size, that might otherwise be missed if pathways information is ignored. In a simulation study
we demonstrated that where causal SNPs are enriched within a single causal pathway, SGL
does indeed have greater SNP selection power, compared to an alternative sparse regression
model, the lasso, that disregards pathways information. These results mirror previous findings
that support the intuition that a sparse selection penalty that promotes dual-level sparsity is
better able to recover the true model in these circumstances [26, 69].
We then argued from a theoretical standpoint that where individual SNPs can map to
multiple pathways, a modification (SGL-CGD) of the standard SGL-BCGD estimation algo-
rithm that treats pathways as independent, may offer greater sensitivity for the detection of
causal SNPs and pathways. A potential concern is that this gain in power may be accompa-
nied by an inflated number of false positives. However, in a simulation study with overlapping
pathways we found relative gains in both sensitivity and specificity, under the independence
assumption. This gain in specificity was unexpected, and appears to arise directly from treat-
ing pathways as independent in the model estimation. As with the group lasso, the ability
of SGL to recover the true model is likely to be affected by the complexity of the pathway
overlap structure [60], although we expect that the gains in power and sensitivity achieved
with the independence assumption will also be apparent with real data.
Our method combines the SGL model and SGL-CGD estimation algorithm with a weight-
tuning algorithm to reduce selection bias, and a resampling technique designed to provide a
robust measure of SNP, gene and pathway importance in a finite sample. As such, the latter
is expected to confer advantages, in terms of the down ranking of unimportant predictors,
previously observed for the lasso [54, 13]. Once again it would be interesting to explore this
further using simulations derived from real pathway and genotype data.
We do not explore the issue of determining a selection frequency threshold for the control of
false positives here. In principal such a threshold could be determined by comparing empirical
selection frequency distributions with those obtained under the ‘null’, through permutations,
although this is not a trivial exercise [83]. An alternative method for error control has been
investigated in the context of lasso selection [54], but the direct application of this approach
to the present case is not feasible, since overlapping pathways make clear distinctions between
causal and noise variables problematic. We instead develop a heuristic measure of ranking
performance in our application study identifying SNPs and pathways associated with serum
high-density lipoprotein cholesterol levels (HDLC). Firstly, by comparing empirical and null
pathway and SNP rankings for each dataset, we gain some confidence that pathway and SNP
signals captured in the top rankings can be distinguished from those arising from noise or
spurious associations. Secondly, we take advantage of the fact that we are able to compare
results from two independent GWAS datasets. On the assumption that similar patterns of
genetic variation are likely to impact HDLC levels in both cohorts, we set a ranking threshold
based on computing distances between ranked lists from each dataset.
Interestingly, when a comparison between empirical and null rankings is made with a
reduced value for the regularisation parameter α, there is evidence of selection bias, in the
sense that pathways and SNPs tend to be highly ranked both empirically and under the
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null (see Figures 10 and 11). Since a smaller α corresponds to a greater number of SNPs
being selected at each subsample, this would seem to suggest that too many SNPs are being
selected. In this case, pathway and SNP rankings may in part reflect spurious associations,
with a bias towards SNPs overlapping multiple pathways.
There are other potentially interesting areas to explore with regard to the subsampling
method used here. For example, standard approaches consider only the set of variables
selected at each subsample, and ignore potentially relevant information captured in the co-
efficient estimates themselves. The use of this additional information would result in a set
of ranked lists, one for each subsample, and the joint consideration of these lists has the
potential to provide a more robust measure of variable importance, by taking account of the
relative importance of each variable for each subsample [64, 47, 43].
Turning to the study results, we conduct two separate analyses on independent discov-
ery and replication datasets. Since subjects from both datasets are genotyped on the same
platform, the large majority of SNPs mapping to pathways in one dataset do so also in the
other dataset. Thus 99.3% of SNPs mapping to pathways in the SP2 dataset are similarly
mapped in the SiMES dataset. For the SiMES dataset, the corresponding figure is 94.8%.
As expected, the concordance of gene coverage is even greater. Thus 99.8% of mapped genes
in the SP2 dataset are also mapped in the SiMES dataset, and 99.5% of mapped genes in
the SiMES dataset are also mapped in SP2. This large overlap in gene (and pathway) cov-
erage between datasets is likely to occur even when datasets are genotyped on different SNP
arrays. Indeed this is one advantage of methods such as the one described here that enable
comparisons between pathway and gene rankings.
We obtain consensus pathway and gene rankings by considering only the top k ranks
in each dataset, with k obtained as the value that minimises the distance between the two
rankings. We additionally derive a significance measure for each top-k distance by comparing
empirical distances against a null distribution obtained by permuting ranks in one list. We
note that this can only be an approximation of the true null, since in reality rankings for
both datasets may be influenced by the extent to which genes and SNPs overlap multiple
pathways. However, some support for the reasonableness of this approximation can be gained
from our earlier analysis, showing that the correlation between empirical and null pathway
and SNP rankings is low, so that rankings under the null are indeed approximately random.
Considering the consensus pathway rankings in Table 11, three out of the seven consensus
pathways (ranked 1, 2 and 5), are related to cardiomyopathy. These three pathways are the
only cardiomyopathy-related pathways amongst the 185 KEGG pathways used in our analysis,
so it is noteworthy that all three fall within the consensus pathway rankings. The link between
HDLC levels and cardiomyopathy is already well established [1, 29, 81, 24, 27]. Furthermore,
numerous references in the literature also describe the links between lipid metabolism and T
cell receptor (consensus pathway ranking 3) and PPAR signaling (rank 7) [40, 9, 73, 6].
Turning to a consideration of the top 30 consensus genes and SNPs presented in Tables
13 and 15 (and see also pathway ranking tables 6, 9 and 11, and extended results in supple-
mentary information). We found that many are enriched in one of several gene families:
1. L-type calcium channel genes, including CACNA1C, CACNA1S, CACNA2D1, CACNA2D3
and CACNB2
2. Adenylate cyclase genes, including ADCY2, ADCY4 and ADCY8
3. Integrin and laminin genes, including ITGA1, ITGA9, ITGA11, LAMA2, and LAMA3
41
4. MAPK signaling pathway genes, including MAPK10 and MAP3K7
5. Immunological pathway genes, including PAK2, PAK7, PRKCA, PRKCB, VAV2 and
VAV3
These genes are highly enriched in several high ranking pathways from both datasets.
Notably, the focal adhesion pathway alone has 12 gene hits, as does the dilated cardiomyopa-
thy pathway. Cardiomyopathy pathways as a whole have 30 genes hits (several of the genes
overlap more than one cardiomyopathy pathway). 10 of these genes feature in the MAPK
signaling pathway, while GnRH (8 genes), T and B cell receptor (8), calcium (7), ErbB (5),
and Wnt signling (4) pathways also contain several genes in the list. To elucidate the bio-
logical relevance of these gene families and the connections between them, we investigated
their known functional links with cardiovascular phenotypes (not restricted to HDLC) by ref-
erencing the KEGG and Genetic Association (http://geneticassociationdb.nih.gov) databases.
Voltage dependent L-type calcium channel gene family
The genes in this family encode the subunits of the human voltage dependent L-type calcium
channel (CaV1). The α-1 subunit (encoded by CACNA1C, A1S, A2D1 and A2D3 in our
study) determines channel function in various tissues. CaV1 function has significant impact
on the activity of heart cells and smooth muscles. For example, patients with malfunctioning
CaV1 develop arrhythmias and shortened QT interval [72, 2, 75]. Furthermore, CACNA1C
polymorphisms have been associated with variation in blood pressure in Caucasian and East
Asian populations by pharmacogenetic analysis. In 120 Caucasians, 3 SNPs in this gene were
significantly associated with the response to a widely applied antihypertensive CaV1 blocker
[8]. Kamide et al. [45] also found that polymorphisms in CACNA1C were associated with
sensitivity to an antihypertensive in 161 Japanese patients. The CaV1 β subunit encoding
CACNB2 has also been associated with blood pressure [49].
This gene family was mapped to several pathways in our study, with the KEGG dilated
cardiomyopathy pathway achieving highest rank both within individual datasets, and in the
consensus pathway rankings. Dilated cardiomyopathy is the most common form of cardiomy-
opathy, and features enlarged and weakened heart muscles. Although high levels of serum
HDLC lowers the risk of heart disease [12, 81], there is still no direct evidence that CaV1 is
involved in HDLC metabolism.
Adenylate cyclase gene family
Three adenylate cyclases genes, ADCY2, ADCY4 and ADCY8 were highly ranked in our
study. Currently, there are no reported associations of these genes with cardiovascular disease
or lipid levels. Adenylate cylcase genes catalyse the formation of cyclic adenosine monophos-
phate (cAMP) from adenosine triphosphate (ATP), while cAMP servers as the second mes-
senger in cell signal transduction. Note that ADCY2 is insensitive to calcium concentration,
suggesting that any association of this gene family with HDLC levels may not be due to any
interactions with the CaV1 gene family.
Among high ranking pathways, ADCY2 and ADCY8 feature in the dilated cardiomyopa-
thy pathway. Although ADCY4 was not in the top 30 consensus genes, rs751877 in this gene
was among the top 30 consensus SNPs.
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Integrin and laminin gene families
We found 3 genes encoding integrin subunits in our study. Integrins hook to the extracellular
matrix (ECM) from the cell surface, and are also important signal transduction receptors
which communicate aspects of the cell’s physical and chemical environment [58]. Interestingly,
laminins are the major component of the ECM, and are relevant to the shape and migration of
almost every type of tissue. Both of these two families of genes are therefore highly relevant to
the survival and shape of heart muscles. A recent GWAS conducted in a Japanese population
confirmed a previous association between ITGA9 and blood pressure in European populations
[74].
Integrin family genes and LAMA2 were selected primarily within high-ranking cardiomy-
opathy, focal adhesion and ECM receptor signaling pathways, with once again the dilated
cardiomyopathy pathway achieving the highest ranks. However, evidence for LAMA3 asso-
ciation is weaker, since it was not in the top 30 consensus genes, although a SNP from the
LAMB3 (laminin β-3) gene was ranked 29 in the consensus SNP list.
MAPK signaling pathway
TAK1 (MAP3K7 ) and JNK3 (MAPK10 ) are kinases which regulate cell cycling. They acti-
vate or depress downstream transcription factors which mediate cell proliferation, differenti-
ation and inflammation.
JNK activity has been associated with obesity in a mouse model, where the absence of
JNK1 (MAPK8 ), a protein in the same family as MAPK10, protects against the obesity-
induced insulin resistance [33]. The negative correlation between HDLC level and obesity has
been well accepted [36].
Immunological pathways
PAK (PAK2 and PAK7 ) genes feature in the high ranking T cell signaling pathway in both
SP2 and SiMES datasets. PRKC (including PRKCA and PRKCB), along with VAV (VAV2
and VAV3 ) genes also feature in various high ranking immunological pathways including T
cell signaling, Pathogenic Escherichia Coli Infection and Natural Killer Cell Mediated Cyto-
toxicity. Genes from all 3 of these families are frequently top ranked in these pathways.
PAK and VAV are activated by antigens, and regulate the T cell cytoskeleton, indicating
a possible impact on T cell shape and mobility. In a candidate gene association analysis,
PRKCA was reported to be associated with HDLC at a nominally significant level, but was
not significant after adjusting for multiple testing [51].
In summary, genes enriched in the above gene clusters and pathways may be relevant to
heart muscle cell signal transduction, shape and migration, and may thus have functional
relevance to the onset of cardiovascular diseases. Many highly ranked genes in our study
are also involved in neurological pathways. For example polymorphisms in CACNA1C have
been associated with bipolar disorder, schizophrenia and major depression [22, 55, 30]. This
points to an interesting hypothesis that serum HDLC levels might be regulated not only
by metabolism but also by neurological pathways, although the elucidation of any putative
biological mechanism underlying such an association obviously exceeds the scope of this study.
Besides the gene families and associated pathways discussed above, a notable feature of the
top 30 consensus SNP ranking results presented in Table 15 is the inclusion of 9 SNPs mapping
to the PDSS2 gene. PDSS2 achieves its high ranking in the consensus SNP list, through its
inclusion in the highly ranked terpenoid backbone biosynthesis pathway in SiMES, and this
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gene is in fact the second highest consensus ranking gene with this dataset. In contrast, this
gene is ranked low (216) in the SP2 dataset, which explains why it fails to make the top 30
consensus gene rankings. PDSS2 encodes subunit 2 of prenyl diphosphate synthase, which
determines the length of the isoprenoid chain of coenzyme Q10 (CoQ10) [61]. A deficiency in
biosynthesis of CoQ10 has previously been associated with delayed motor development and
abnormal renal function, with excess serum lipids [70].
Despite the well established links between lipid metabolism and PPAR signaling noted
above, no genes in this high-ranked pathway fall in the top 30 gene rankings for either dataset
(see Tables 6 and 15). This could be because the association signal in this pathway is more
widely distributed, compared to other high ranking pathways, perhaps indicating hetero-
geneity in genetic causal factors within our sample, so that different genes and SNPs are
highlighted in different subsamples. This would result in reduced gene selection frequencies.
Also, genes that overlap multiple putative causal pathways are more likely to be selected in
a given subsample, meaning that associated genes mapping to pathways with relatively few
overlaps may have lower selection frequencies. This may be the case with genes in the PPAR
signaling pathway, whose 63 genes map to an average 2.7± 1.8 pathways. As a comparison,
the 84 genes in the top-ranked dilated cardiomyopathy pathway map to an average 7.2± 3.8
pathways.
Our study failed to highlight HDLC-associated SNPs identified in previous GWAS (see
for example www.genome.gov/gwastudies for an up to date list). A primary reason for this
is that the large majority of SNPs identified in previous studies do not map to pathways in
our study, either because they fall in intergenic regions, or because they do not feature on
the Illumina arrays used here. In addition our method is designed to highlight distributed,
small SNP effects that accumulate across gene pathways, and so will likely fail to identify
those SNPs with significant marginal effects targeted by GWAS. Furthermore, where there
are common mechanisms affecting phenotypes in both cohorts, we would expect to observe
the most concordance between the two studies at the pathway level, followed by genes, and
lastly SNPs. Indeed this increased heterogeneity at the SNP, and to a lesser extent at the
gene level is one motivation for adopting a pathways approach in the first place [35, 34,
10]. This reduced concordance at the SNP level may be due to increased heterogeneity of
genetic risk factors between the two datasets. Another important source of variation in SNP
selection frequencies is LD between SNPs. The within-pathway lasso penalty will tend to
select one of a group of highly correlated SNPs at random, reducing SNP selection frequencies
within LD blocks harbouring causal SNPs. An alternative approach would be to consider a
different penalty within selected pathways, for example the elastic net [92], which selects
groups of correlated variables jointly, although this comes at the cost of introducing a further
regularisation parameter to be tuned.
Finally, as with all pathways analyses, a number of limitations with this general approach
should be noted. Despite great efforts, pathway assembly is still in its infancy, and the
relative sparsity of gene-pathway annotations reflects the fact that our understanding of how
the majority of genes functionally interact is at an early stage. As a consequence, annotations
from different pathways databases often vary [71], so that the choice of pathways database will
impact results [19, 10]. Results are also subject to bias resulting from SNP to gene mapping
strategies, so that for example SNP to gene mapping distances will affect the number of
unmapped SNPs falling within gene ‘deserts’ [20]; SNPs may map to relatively large numbers
of genes in gene rich areas of the genome; and the mapping of a SNP to its closest gene
may obscure a true functional relationships with a more distant gene [87]. Indeed recent
44
research from the ENCODE project indicates that functional elements may in fact be densely
distributed throughout the genome [7, 62], and this information has the potential to radically
alter future pathways analysis. These issues, together with the fact that PGAS methods
are by construction designed to highlight distributed, moderate to small SNP effects, serve
to further illustrate the point that pathways analysis should be seen as complementary to
studies searching for single markers [86].
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Supplementary Information
A SGL estimation algorithm
For the estimation of βSGL we proceed by noting that the optimisation (1) is convex, and
(in the case of non-overlapping groups) that the penalty is block-separable, so that we can
obtain a solution using block, or group-wise coordinate descent [82]. For a single group, l, the
corresponding minimising function is given by
f(βl) =
1
2
||y −Xβ||22 + (1− α)λwl||βl||2 + αλ||βl||1. (11)
An optimal solution for SNP coefficient βj is then derived from the subgradient equations
− x′j(rˆl −
∑
k 6=j
xkβˆk − xjβj) + (1− α)λwlsj + αλtj = 0 j = l1, . . . , lPl , (12)
where βˆk, k 6= j are the current estimates for other SNP coefficients in group l, and the group
partial residual, rˆl = y −
∑
m 6=lXmβˆm. Here sj and tj are the respective subgradients of
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||βl||2 and |βj |, with
sj =
{
βj
||βl||2 if ||βl||2 6= 0
∈ [−1, 1] if ||βl||2 = 0
tj =
{
sign(βj) if βj 6= 0
∈ [−1, 1] if βj = 0.
(13)
If βl = 0, that is group l is not selected by the model, then from (12)
− x′j rˆl + (1− α)λwlsj + αλtj = 0, j = l1, . . . , lPl . (14)
Substituting a = X′lrˆl gives
aj = (1− α)λwlsj + αλtj , j = l1, . . . , lPl
so that
s2j =
1
(1− α)2λ2w2l
(aj − αλtj)2, j = l1, . . . , lPl ,
and ∑
j
s2j =
1
(1− α)2λ2w2l
∑
j
(aj − αλtj)2.
From (13), when βl = 0, ||s||2 = (
∑
j s
2
j )
1
2 ≤ 1, so that∑
j
(aj − αλtj)2 ≤ (1− α)2λ2w2l . (15)
Also from (13), one further condition when βl = 0 is that tj ∈ [−1, 1]. The values, tˆj that
minimise the left hand size of (15) are therefore given by
tˆj =
{
aj
αλ if |
aj
αλ | ≤ 1
sign(
aj
αλ) if |
aj
αλ | > 1.
Substituting for aj , we can then write the values for aj − αλtj that minimise the left hand
side of (15) as
aj − αλtj =
{
0 if |x′j rˆl| ≤ αλ
sign(x′j rˆl)(|x′j rˆl| − αλ) if |x′j rˆl| > αλ
= S(x′j rˆl, αλ)
for j = l1, . . . , lPl , where
S(x′j rˆl, αλ) = sign(x
′
j rˆl)(|x′j rˆl| − αλ)+ (16)
is the lasso soft thresholding operator. Finally, we can now rewrite the condition for βˆl = 0,
(15) as
||S(X′lrˆl, αλ)||2 ≤ (1− α)λwl, (17)
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Where the vector S(X′lrˆl, αλ) = [S(x
′
l1
rˆl, αλ), . . . , S(x
′
lP
rˆl, αλ)]. Note that with α = 0, this
reduces to the group lasso group selection criterion.
In the case that βl 6= 0, that is group l is selected by the model, from (12) and (13) we
see that βj = 0 when
− x′j(rˆl −
∑
k 6=j
xkβˆk) ≤ |αλ|. (18)
For completeness, we rewrite the criterion for selecting pathway l from (17) as
||S(X′lrˆl, αλ)||2 > (1− α)λwl (19)
and the criterion for selecting SNP j in selected pathway l from (18) as
|x′j rˆl,j | > αλ (20)
where rˆl,j = rˆl−
∑
k 6=j xkβˆk is the SNP partial residual, obtained by regressing out the current
estimated effects of all other predictors in the model, except for predictor j.
A number of methods for the estimation of βl in the case that ||βl||2 6= 0 have been
proposed [26, 23, 50, 69]. A complicating factor is the discontinuities in the first (and second)
derivatives of sj at ||βl||2 = 0, that is where ||βl||2 first moves away from zero, and of tj when
βj = 0. As with GL, Friedman, Hastie, and Tibshirani [26] describe a numerical method
using coordinate descent, by combining a golden search over βj with parabolic interpolation.
However we find this too computationally intensive for the large datasets we wish to analyse.
Simon et al. [69] propose an accelerated, block gradient descent method in which βl is itera-
tively updated in a single step along the line of steepest descent of the block objective function
until convergence. We instead use a block, coordinate-wise gradient descent (BCGD) method
that uses a Newton update, similar to that proposed by Zhou et al. [91], and we describe this
below.
To update βj from its current estimate, βˆj , we note from (12) and (13) that if βˆj 6= 0, the
subgradient equation for predictor j is given by
∂j = −x′j(rˆl −Xlβˆl) + (1− α)λwl
βˆj
||βˆl||2
+ αλ · sign(βˆj). (21)
We then descend along the gradient at βˆj towards the minimum using Newton’s method.
The Newton update, β∗j , is then given by
βˆ∗j = βˆj −
∂j
∂′j
,
where ∂′j = 1 +
(1− α)λwl
||βˆl||2
(
1− βˆ
2
j
||βˆl||22
) (22)
is the derivative of (21) at βˆj . The update (22) is repeated until convergence.
We must also deal with the case where βˆj = 0. Here we adopt a slightly different strategy,
since the partial derivative, tj of βj is not continuous. We avoid this discontinuity by testing
the ‘directional derivatives’, ∂+j and ∂
−
j , respectively representing the partial derivatives at
βj = 0 in the direction of increasing and decreasing βj . Recalling that we are dealing with
the case ||βl||2 6= 0, at βj = 0 the group penalty term in (21) disappears. That is, once a
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group is selected by model it becomes easier for each SNP coefficient to move away from zero.
The two directional derivatives are then given by
∂+j = −x′j(rˆl −Xlβˆl) + αλ
∂−j = −x′j(rˆl −Xlβˆl)− αλ.
(23)
Since the minimising function (11) is convex, there are three possible outcomes, and we
substitute for ∂j in (22) accordingly:
∂j ←

∂−j if ∂
−
j > 0 and ∂
+
j > 0
∂+j if ∂
−
j < 0 and ∂
+
j < 0
0 if ∂−j > 0 and ∂
+
j < 0
(24)
In the third case, f(βl) is increasing either side of βj = 0, so that βˆj must remain at zero.
We can then proceed with the standard Newton update (22).
Finally, since the Newton update may occasionally overstep the minimum (where ∂j = 0),
a simple remedy proposed by Zhou et al. [91] is to check that f(βl) is decreasing at each
iteration. If this is not the case, then the step size in (22) is halved. The complete algorithm
for SGL estimation using BCGD is presented in Box 1.
One remaining practical issue is the obtaining of a value for λmax, the smallest value of
λ at which no groups are selected by the model. Noting that rˆl = y when no groups are
selected, from (17) we obtain the smallest value, λminl , for the minimum value of λ at which
group l is not selected as
λminl =
||S(X′ly, αλminl )||2
(1− α)wl (25)
We can solve this in its quadratic form by first setting an upper bound for λ at the point λ∗l ,
where the soft thresholding function S(X′lyl, αλ) = 0, that is when no SNPs are selected by
the model. We then obtain the solution by solving
||S(X′ly, αλminl )||22 − (1− α)2(λminl )2w2l = 0 0 < λminl < λ∗l (26)
for λminl , where
λ∗l = max
j
|x′jy|
α
, j = l1, . . . , lPl .
We do this using the 1d root-finding function, brentq, in Python’s scipy library. Finally, we
obtain a value for λmax as
λmax = max
l
λminl , l = 1, . . . , L. (27)
B SGL with overlaps
We assume that X and β have been expanded to account for overlaps, but we drop the ∗
notation for clarity. We proceed as before by solving the block-separable optimisation (4)
for each group or pathway in turn. However, for overlapping pathways, the assumption
of pathway independence requires that each Xl, (l = 1, . . . , L) is regressed against the full
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phenotype vector y rather than the partial residual, rˆl. With this in mind, the revised
subgradient equations for group l (12) are given by
− x′j(y −
∑
k 6=j
xkβˆk − xjβj) + (1− α)λwlsj + αλtj = 0 j = l1, . . . , lPl . (28)
The estimation for group l then proceeds as described in the previous section, but with
the partial residual rˆl replaced by y, so that the group sparsity condition (17) for ||βˆl||2 = 0
becomes
||S(X′ly, αλ)||2 ≤ (1− α)λwl. (29)
As before, where group l is selected by the model, the update for βj , with current estimate
βˆj , is derived from the partial derivative (21), which under the independence assumption is
given by
∂j = −x′j(y −Xlβˆl) + (1− α)λwl
βˆj
||βˆl||2
+ αλ · sign(βˆj), (30)
for j = l1, . . . , lPl . The Newton update (22) remains the same. When βˆj = 0, the revised
directional derivatives (23) are given by
∂+j = −x′j(y −Xlβˆl) + αλ
∂−j = −x′j(y −Xlβˆl)− αλ.
(31)
As before the conditions for SNP sparsity within a selected group are determined by (24).
The value of λmax, the smallest λ value at which no group is selected by the model, is
determined in the same way as before, since this procedure (described in (25), (26) and (27))
does not depend on rˆl.
Importantly, since each group is regressed independently against the phenotype vector y,
there is no block coordinate descent stage in the estimation, that is the revised algorithm
utilises only coordinate gradient descent within each selected pathway. For this reason we
use the acronym SGL-CGD for the revised algorithm. The new algorithm is described in Box
2. Note that since the block coordinate descent stage is avoided, the new algorithm has the
added benefit of being much faster than would otherwise be the case.
C Simulation study 1
A baseline phenotype, y is sampled from N (10, 1). To generate SNP effects, we first select a
single pathway, Gl, at random. From this pathway we randomly select 5 SNPs to from the
set S ⊂ Gl of causal SNPs. At each MC simulation we generate a genetic effect and adjust y
so that
y∗ = y + w
where
w = δ
∑
k∈S
ζkxk.
Here δ controls the overall additive genetic effect on phenotype y due to all casual SNPs in S,
and ζk determines the contribution from causal SNP k, with
∑
k∈S ζk = 1. In our simulations
we maintain a constant overall genetic effect size,
γ = E(w)/E(y)
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across all affected phenotypes, so that γ represents the proportionate increase in the mean
value of y due to all genetic effects. We also set ζk = 1/5, for k ∈ S, so that the contribution
from each causal SNP allele is equal. This enables us to determine δ for a given γ as
δ =
5γE(y)
2
∑
k∈S mk
.
Note that for constant γ, the proportionate effect on the mean value of y due to SNP k is
MAF dependent, and is given by 2δmk/E(y).
D Weight tuning for bias reduction
For fixed α, and with λ tuned to select a single pathway, we need to establish which pathway
enters the model first, as λ is reduced from its maximal value, λmax. From (27), at phenotype
permutation r, the pathway Cˆr selected with permuted phenotype yr is given by
Cˆr = arg max
l
λminl , , l = 1, . . . , L.
λminl is obtained by solving
λminl =
||S(X′lyr, αλminl )||2
(1− α)wl ,
using the procedure described at the end of Section A. For R permutations of the phenotype
vector, y, the empirical pathway selection frequency distribution is then given by
Π∗(w) =
1
R
R∑
r=1
{Cˆr = l}, l = 1, . . . , L.
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